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Summary  
 
Cardiovascular disease is the leading cause of death in surgical patients and because 
of this a number of strategies have been utilised to attempt to predict the cardiac risk 
of surgery. Theoretically, accurate pre-operative risk stratification would allow 
patients at low risk to have their surgery expedited efficiently, whilst those at higher 
risk could have a change made to their treatment plan such as peri-operative cardiac 
optimisation or in some cases, modification of the operative procedure.  Despite this 
rationale, no guidelines currently exist in the United Kingdom for the management of 
the surgical patient at high cardiac risk. This may partly reflect the limited methods of 
risk stratification currently available. Clinical scoring systems are simple and 
inexpensive but limited by their predictive value. Trans-thoracic echocardiography 
provides prognostic information but is inconsistent, adding little to clinical 
information alone. The most accurate methods of pre-operative cardiac risk prediction 
at the present time are dobutamine stress echocardiography and dipyridamole thallium 
scanning. However they are expensive, time consuming and have shown poor positive 
predictive ability, even in high risk cohorts. 
 
Few studies have studied the usefulness of biochemical markers in the prediction of 
post-operative cardiac events. In particular, no information was available in the 
literature regarding the role of B-type natriuretic peptide (BNP) in the prediction of 
cardiac events in non-cardiac surgical patients; despite the fact that its measurement 
has been shown to be an important prognostic tool in both non-surgical and cardiac 
surgical cohorts. In this thesis the aim was to determine whether pre-operative BNP 
concentration related to cardiac outcome following non-cardiac surgery; and also to 
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determine whether measurement of other markers such as C- reactive protein (CRP) 
and cardiac troponin I (CTnI) would be of benefit in pre-operative cardiac risk 
stratification.  
 
To assess the effectiveness of plasma BNP measurement in the prediction of peri-
operative cardiac morbidity a pilot study of 41 patients undergoing vascular surgery 
was conducted. To ensure that any post-operative rise in CTnI was due to operative 
stress, this was measured pre-operatively along with CRP. Median pre-operative BNP 
concentration was significantly higher in patients who suffered a post-operative 
cardiac event (cardiac death, non-fatal myocardial infarction (MI)) than in those who 
did not (210 (165-380) pg/ml vs. 34.5 (14-70) pg/ml, p<0.001). On the basis of these 
results a single-centre, prospective, observational cohort study was performed of all 
patients undergoing non-cardiac surgery. Of the 149 patients recruited to this study, 
15 had a cardiac event. The median BNP in those patients having a cardiac event was 
more than ten-times higher than in those who did not (351 (127-1034) vs. 30.5 pg/ml 
(11-79.5), p<0.001). A BNP concentration of 108.5pg/ml was the best performing 
cut-off value having a sensitivity and a specificity of 87%.  
 
Although CTnI had originally been measured to ensure that any post-operative rise 
was due to operative stress, 3 patients had a pre-operative elevation all of whom 
underwent lower extremity amputation. The amputation group, and in particular those 
patients who had a raised pre-operative cTnI were therefore analysed further. 
Amputation patients in general had a high cardiac event rate (23%); however the 
outcome in those patients who had a raised pre-operative cTnI was particularly poor 
with 2 suffering a cardiac death post-operatively and one suffering a non-fatal MI. A 
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pre-operative rise in CTnI was the only significant single predictor of peri-operative 
cardiac events in patients undergoing amputation (p= 0.009).  
 
Pre-operative CRP concentration was measured routinely in vascular patients. The 
concentration in those who had a cardiac event was significantly higher than those 
who did not (69 (0-260) vs. 12 (0-285), (p=0.003). The cardiac event rate rose with 
each logarithmic increment in CRP concentration (0-10mg/l (5.7%); 11-100mg/l 
(22.4%), >100mg/l (55.6%) (p=0.002). Measurement of CRP was of most potential 
benefit in patients undergoing aortic aneurysm surgery.  
 
In conclusion, this thesis has shown that pre-operative measurement of biochemical 
markers (BNP, CTnI, and CRP) can allow accurate peri-operative risk stratification. 
BNP concentration in particular was a sensitive and specific predictor of cardiac 
outcome. Careful case selection using a combination of clinical assessment and the 
results of these markers may lead to a reduction in the cardiac event rate. 
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1.1 Peri-operative cardiac morbidity- the problem 
 
Major general surgery and vascular surgery in particular, can carry considerable risk 
of cardiac morbidity. Cardiovascular disease is the leading cause of mortality in 
surgical patients and estimates suggest that 5% of the surgical population worldwide, 
(5 million patients annually) suffer some form of peri-operative cardiac morbidity 
(Mangano 1990). This is substantiated by a report from a surgical database of 83958 
US male veterans which found that 4.5% suffered a peri-operative cardiac event 
(Khuri et al. 1995). The incidence of coronary artery disease is higher in Scotland than 
in many other countries, therefore it would be logical that cardiac complications post-
operatively would also be higher in Scotland. Data from the Scottish Audit of Surgical 
Mortality illustrates the problem (Scottish audit of surgical mortality summary report, 
2004). In Scotland in 2003 there were 370 myocardial infarctions in non-cardiac 
surgical patients. Of 1894 peri-operative deaths in that year, 578 were cardiac in 
origin, this being the commonest cause of mortality. 
 
The impact of peri-operative myocardial infarction (MI) is substantial. It leads to 
increased short and long term mortality, a greater length of hospital stay, and 
increased costs (Khuri et al. 1995;L'Italien et al. 1995;McFalls et al. 1998).  Accurate 
cardiac risk prediction with appropriate intervention could therefore be of 
considerable benefit.   
 
1.2 The presentation and aetiology of peri-operative myocardial infarction 
Peri-operative MI occurs most commonly on the first to third days post-operatively, 
with more recent studies of incidence reporting an increased frequency on the first 
day (Badner et al. 1998;Mangano et al. 1990;Raby et al. 1992). Peri-operative MI is 
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often clinically silent with as few as 17% of affected patients having symptoms of 
chest pain (Badner et al. 1998). This may be due to the residual effects of the 
anaesthetic and analgesia or competing incisional pain (Raby et al. 1992). 
Furthermore, non-q wave MI has a greater incidence post-operatively than in the 
general setting (Badner et al. 1998;Fleisher et al.1995;Goldberg et al. 1987). This may 
be because post-operative MI is more commonly due to prolonged ischaemia rather 
than sudden acute rupture of coronary atherosclerotic plaques.  
 
Peri-operative MI represents an imbalance of oxygen supply and requirement. 
Decreased supply may result from rupture of a coronary atherosclerotic plaque, 
coronary vasoconstriction (secondary to catecholamine stimulation of ά1 adrenergic 
receptors), hypotension, anaemia or hypoxia (Breslow 1992). Increased demand 
results from post-operative tachycardia and hypertension secondary to withdrawal of 
anaesthesia, peri-operative pain and fluid shifts (Breslow 1992;Mangano et al. 
1990;Raby et al. 1992).  The aetiology and patho-physiology of peri-operative MI may 
differ from those in the general setting. The commonest cause in the non-surgical 
setting is from rupture of a coronary atherosclerotic plaque; often in 
haemodynamically insignificant lesions, leading to platelet aggregation and thrombus 
formation (Fuster et al. 1992, Fuster 1994)). In contrast, it has been suggested that up 
to half of peri-operative MIs are due to an imbalance in oxygen delivery and 
requirement caused by the stress of surgery in the setting of coronary heart disease 
(Grayburn & Hillis 2003). This view is supported by studies showing that deliberately 
increasing oxygen supply can reduce peri-operative cardiac morbidity (Boyd et al. 
1992).  
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One such study, a randomised controlled trial of 107 high risk surgical patients, found 
that maximising the delivery of oxygen (to a target of 600ml/min/m2) using 
dopexamine significantly reduced the overall morbidity (p= 0.015) and mortality 
(p=0.008) (Boyd et al. 1993). There were 8 (15.1%) cardiac events in the treatment 
group compared with 16 (29.6%) in the control group. However, the study had some 
weaknesses; there was no description of the surgical procedures performed, clinicians 
were not blinded to patients grouping, and 24 of 107 patients were entered into the 
study post-operatively. Furthermore, the extremely high 30-day mortality (22% in the 
control group) suggests that this study is not representative of normal clinical practice. 
 
Wilson et al (1999) conducted a similar randomised controlled trial, again showing 
that increasing oxygen delivery to a target of 600ml/min/m2) with the use of 
dopexamine reduced both overall mortality and cardiac morbidity. In this study, the 
138 patients received dopexamine, adrenaline or standard care. The mortality rate in 
those patients whose delivery of oxygen was optimised was 3% compared with 17% 
in the control groups (p=0.007). There were 14 (30.4%) cardiac events in the 
dopexamine group compared with 29 (63%) in the control group. Randomisation was 
carried out by a computer and patients were studied on an intention to treat basis. 
However the study was not blinded and there was a significant reduction in the critical 
care bed provision in the control group. Once again the 30-day mortality (in this case 
17%) in the control group was higher than one would expect in normal practice, 
raising doubt about whether the findings are applicable to general use.  
 
Two separate pathological studies have shown that half of fatal post-operative MIs are 
secondary to rupture of coronary atherosclerotic plaque. Dawood et al (1996) 
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retrospectively studied the coronary arteries and myocardium at autopsy of 42 patients 
who had suffered a fatal peri-operative MI and compared them with those of 25 
patients who had suffered a fatal non-operative MI. Findings were similar in the two 
groups. Three vessel coronary artery disease was present in 59% of the operative 
group and 60% of the non operative group. There was evidence of plaque disruption 
in 55% of the operative group compared with 40% of the non-operative patients. In 
both groups the acute coronary lesion almost invariably correlated with the site of 
infarction, but the severity of pre-existing underlying stenosis did not predict the 
resulting infarct territory. Cohen and Aretz (1999) also studied autopsy specimens of 
patients suffering a peri-operative MI. Multi-vessel coronary artery disease was 
present in 88% of the 26 specimens included. 50% of patients showed evidence of 
plaque rupture and 35% had evidence of intra-coronary thrombus.  There was a longer 
interval from surgery to death in those patients with plaque rupture. In 19% of 
patients the territory of MI had a circumferential distribution suggesting a diffuse lack 
of oxygen. Both studies were limited by small numbers, patient selection bias, and the 
fact that the groups represent only fatal peri-operative MI. Furthermore the coronary 
arteries were not fixed in distension and some of the observed narrowing could have 
resulted from post-mortem collapse. The studies may also have under-represented the 
incidence of intra-coronary thrombus due to spontaneous lysis after the event. 
However their findings are consistent, in that they show that ruptured atherosclerotic 
plaque is as important a cause of MI in the peri-operative setting as in the general one. 
Observations that a diffuse lack of oxygen plays a more significant role may therefore 
not be valid. 
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1.3 Predicting peri-operative cardiac morbidity 
Various strategies have been proposed to improve the prediction of cardiac risk and 
thus allow clinicians a better means of assessing the risk/benefit ratio of a surgical 
procedure. Methods currently utilised include assessment by an experienced clinician, 
simple clinical scoring systems, blood tests, and more complex methods of assessing 
cardiac function.  Accurate peri-operative cardiac risk stratification could allow 
surgery in low risk patients to be expedited efficiently, with moderate risk patients 
being appropriately pre-optimised. A more informed decision could be made about 
the need for surgery in high risk patients, with the management plan being changed if 
appropriate.     
 
1.3.1 Patient factors 
Patient factors that may be predictive of cardiac risk are numerous and include age, 
history of MI, angina pectoris, presence of congestive cardiac failure, diabetes, 
COPD, renal impairment, cerebrovascular disease, history of dysrhythmia and 
ischaemic ECG changes (Detsky et al. 1986;Eagle et al. 1989;Hollenberg et al. 
1992;Lee 1999;Mamode et al. 2001;Poldermans et al. 1995;Raby et al 1992). The 
presence and severity of pre-existing ischaemic heart disease is particularly important 
in determining pre-operative co-morbidity and the Canadian Cardiovascular Society 
has developed an index of angina severity which offers a simple and useful means of 
risk stratification (Campeau 1976). This index has been shown to be as effective as 
some established risk indices in predicting peri-operative cardiac morbidity (Gilbert et 
al. 2000). 
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 Definitions of what constitutes a history of ischaemic heart disease vary between 
studies; however Lee et al (1999b) prospectively studied 4315 surgical patients and  
identified the combination of variables describing pre-operative ischaemic heart 
disease which had the highest correlation with major cardiac complication. These are 
history of MI, history of a positive exercise test, current complaint of chest pain 
considered to be secondary to myocardial ischaemia, use of nitrate therapy, or ECG 
with pathological Q waves. Using, in part, these variables they have developed an 
index of cardiac risk which is discussed later. 
 
1.3.2 Operative factors 
Operative factors are important in determining risk. The type of surgery has 
universally been found to correlate with the likelihood of a cardiac event, although 
there is varying consensus as to the risk associated with individual or groups of 
procedures. Detsky et al (1986) prospectively studied 455 surgical patients. They 
found patients undergoing vascular and orthopaedic surgery to have the highest 
incidence of cardiac events with rates of 13.2% and 13.6% respectively. Patients 
undergoing intraperitoneal or intrathoracic procedures were judged to be at moderate 
risk with 8% of patients suffering an event. Only 2.6% of head and neck patients 
suffered an event.  Eagle et al (1997) retrospectively studied 3368 patients in the 
Coronary Artery Surgery Study population who had undergone non-cardiac surgery. 
Their categorisation of risk of procedure differed from that of Detsky et al. Patients 
undergoing vascular, abdominal, head and neck and thoracic procedures were grouped 
as high risk and had a combined cardiac event rate of greater than 4%, whereas 
orthopaedic, urology and breast patients were deemed low risk, with a combined 
event rate of less than 1%. However the heterogeneity of procedure within each group 
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is likely to confound the estimation of risk derived. Whilst Detsky et al solely 
reported arterial bypass surgery and amputation as vascular procedures, Eagle et al 
included aortic, femoral, renal and peripheral artery surgery as well as venous 
surgery. It is unlikely that the 4.2% of patients undergoing a venous procedure 
contributed to the post-operative cardiac events. Similarly, although urological 
procedures are categorised as low risk, few of the patients in this group underwent 
nephrectomy, the majority undergoing more minor procedures such as a transurethral 
resection of prostate or even dilatation and curettage.  The study conducted by Eagle 
et al may also have overestimated the frequency of cardiac events as the definition of 
MI was subjective; all patients with ECG and enzyme abnormalities strongly 
suggestive of myocardial infarction were included. All post-operative deaths within 
30 days were also judged positive, although not all such deaths would be of cardiac 
origin.  In addition although the study was published in 1997, initial enrolment began 
in 1979 leading to a temporal effect. 
 
 Lee et al (1999b) studied 4315 patients undergoing major non-cardiac surgery and 
found vascular patients to have the highest risk of peri-operative cardiac morbidity 
with a relative risk (RR) of 3.9. Patients undergoing thoracic (RR of 1.1) and 
abdominal (RR of 0.8) surgery were at next highest risk. Orthopaedic patients were 
low risk (RR of 0.4). The prospective nature and large numbers analysed in this study 
add validity to these findings. 
 
Although the cardiac morbidity associated with different groups varies between 
studies, most consistently find that major vascular surgery is of highest risk; although 
this may be as much to do with the co-morbidity of  the patient population as to the 
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stress of surgery (Hertzer et al. 1984). Intra-abdominal and intra-thoracic procedures 
are generally categorised as moderate to high risk. However given the potential 
heterogeneity of these groups of procedure it would perhaps be more relevant to relate 
risk to the precise operation rather than the specialty of operating surgeon. This point 
is illustrated by those studies which have compared rates of cardiac events between 
individual procedures. Mamode et al (2001) found aortic surgery to have a 
significantly higher risk than peripheral vascular or extra-anatomical bypasses with 12 
of the 92 (13%) patients in the aortic group suffering a primary event compared with 
9 of 196 (4.6%) in the other groups (p=0.007) Similarly Fleischer et al (1999)  found 
that  aortic surgery patients (7.8%) had significantly greater 30 day mortality than 
infrainguinal bypass patients (5.8%). The categorisation of patients into “vascular” or 
“abdominal” groups may in some cases be too broad. 
 
The urgency of surgery can also impact on the associated cardiac risk. O’Neill-
Callaghan et al (2005) retrospectively studied 997 patients undergoing vascular 
surgery. Those patients whose procedure was classed as emergency had a 5 times 
greater risk of cardiac event. This is in agreement with the findings of Mangano 
(1990) who found emergency surgery to carry a three times higher cardiac risk. 
 
Intra-operative factors are also important. Back et al (2003) found an operation 
duration of greater than 300 minutes to be a significant predictor of all cause mortality 
when they studied elective vascular patients and Park et al (2001) also showed that 
increased duration of procedure was a significant predictor of events post aortic 
surgery  The occurrence of intra-operative hypotension has also been associated with 
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increased rates of cardiac morbidity and mortality (Cambria et al. 2002;Koness et al. 
1990;Mangano, 1990;Monk et al. 2005). 
 
It is clear that there are a number of operative factors, in addition to the type of 
surgery, which may impact on peri-operative cardiac risk. Whilst one must allow for 
these in any studies of cardiac risk, they may also prove important in interventions to 
reduce peri-operative cardiac morbidity.             
 
1.3.4 Clinical Scoring Systems 
Attempts to combine the most important patient and operative factors and allow some 
objectivity in peri-operative risk stratification have led to the development of clinical 
scoring systems. These systems allow patients to be put into categories of varying 
risk, and may identify those who would benefit from further testing or a change in 
treatment plan. 
 
The American Society of Anaesthesiologists developed a classification of physical 
status in 1963 and found it to be a good predictor of peri-operative mortality 
(American Society of Anaesthesiologists, 1963). However whilst it has been shown to 
be useful in the prediction of all-cause mortality, further study has found it to be 
inaccurate in the prediction of post-operative cardiac complications (Eagle et al. 
1971). 
 
In 1977 Goldman et al (1977) developed their multi-factorial index of cardiac risk in 
non-cardiac surgical patients. Nine risk factors were identified from discriminate 
analysis of cardiac events in this prospective study of 1001 patients. However the 
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model was not validated and the index has performed poorly in studies other than the 
one from which it was derived (Charlson et al. 1987;Lee 1999b). The variable 
weighting given to different risk factors makes it difficult to use and the validity of 
this weighting has been questioned (Howell & Sear 2004). The index is largely of 
historical significance now but its development has led to the formulation of multiple 
scoring systems of varying complexity. 
 
In 1989, Eagle et al (1989)  retrospectively studied a cohort of 200 patients 
undergoing major vascular surgery who had been referred to a nuclear cardiology unit 
for pre-operative assessment. They produced a clinical scoring system dependent on 
five variables which were found to be significant after logistic regression, namely, age 
over 70, diabetes mellitus, history of angina, ventricular ectopics requiring treatment 
and Q-waves on ECG. The presence of none of these criteria places a patient in a low 
risk category, 1or 2 in a moderate risk category and 3 or more in a high risk category. 
In the original study, post-operative ischaemic events occurred in 3.1% of patients 
with no risk factors, 15.5% of patients with 1 or 2 risk factors, and 50% of patients 
with 3 or more risk factors. Failings of the study included the highly selected 
population and the lack of blinding to pre-operative evaluation which led to 44 
patients having their surgery cancelled or postponed. Subjective end points such as 
unstable angina and ischaemic pulmonary oedema were also included. Despite these 
failings, various studies have found the Eagle criteria to be reliable in peri-operative 
cardiac risk stratification, particularly in identifying those patients at low likelihood of 
suffering an event. Poldermans et al (1995) found that an Eagle score of 0 had a 
negative predictive value (NPV) of 99% for cardiac events in their study of 302 
patients undergoing major vascular surgery. They also found a significant difference 
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in cardiac event rates between patients whose scores placed them in the intermediate 
(11%) and high risk (29%) groups. A high Eagle score has also been shown to be 
predictive of adverse events. Back et al (2003) studied 425 consecutive patients 
undergoing elective vascular procedures and found an Eagle score of greater than 2 to 
be a significant predictor of cardiac events. 
 
In 1989 Detsky et al (1999) studied 455 successive patients referred to a general 
medical consultation service prior to undergoing non-cardiac surgery. They found that 
the Goldman Index was not accurate at stratifying risk in this population, having an 
area under the receiver-operating characteristic (ROC) curve of 0.69. They therefore 
modified the original cardiac risk index by simplifying the point system and adding 
angina severity as a variable. This led to an improved area under the ROC curve of 
0.76 and the development of the Detsky score. Whilst this system improved risk 
stratification in this particular cohort, there was concern about the applicability of the 
study given the highly selected population. In 1993 Poldermans et al (1993) found 
that although the Detsky score was significantly higher in patients with peri-operative 
complications, it was of little practical use in risk stratification. They confirmed this 
finding in 1995 in their study of 302 patients undergoing major vascular surgery 
(Poldermans et al. 1995). Despite the fact there was a significant difference in Detsky 
score between those patients having an event and those not, 22 (81%) of the 27 events 
occurred in the low risk group. In their more recent study of 297 patients, Mamode et 
al (2001) have also reported the Detsky score to be an inaccurate predictor of cardiac 
morbidity. 
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Gilbert et al (2000) compared the performance of the indices devised by Goldman, 
Detsky, the American Society of Anaesthesiologists and the Canadian Cardiovascular 
Society (CCS) in their prospective study of 2035 patients undergoing non-cardiac 
surgery. Area under the ROC curve was used to compare the accuracy of stratification 
of each index. No scoring system was found to be significantly better than the others 
and the predictive abilities of all were only moderately better than chance. The CCS 
index performed best with an area under the ROC curve of 0.654. Deficiencies of this 
comparative study included the use of all-cause mortality as an end point and lack of 
any screening for cardiac events. 
 
In 1999, Lee derived and validated a simple modified scoring system for the 
prediction of cardiac risk in noncardiac surgical patients, the revised cardiac risk 
index (RCRI) (Lee et al. 1999b). In the derivation cohort of 2893 patients, 6 factors 
were found to be independently significant in predicting poor cardiac outcome. These 
were high risk of procedure, history of ischaemic heart disease, congestive heart 
failure, history of cerebrovascular disease, insulin therapy for diabetes and raised 
preoperative creatinine. The individual factors were clearly defined and each was 
given equal weighting as ROC analyses did not show any advantage in using the 
weighting derived from the logistic regression analyses. Four of the factors found to 
be independent predictors of outcome in the derivation cohort were confirmed to be 
univariate predictors in the validation cohort of 1422 patients. Diabetes and raised 
preoperative creatinine were not, although they did exhibit a trend to significance. 
Using the presence of these risk factors, patients in the derivation cohort were placed 
into 4 categories of increasing cardiac risk. In this cohort the cardiac risk was 
significantly different between each category. In the validation cohort, although the 
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cardiac risk did increase with each category, the difference only reached statistical 
significant between the second and third categories. The derived index was tested and 
also found to be of benefit in subgroup analysis with higher complication rates in the 
higher risk categories when individual procedures were analysed (with the exception 
of aortic aneurysm repair). The scoring system derived from this study was compared 
with other systems and was shown to significantly outperform the Goldman index and 
the Detsky score (Goldman et al. 1977; Detsky et al. 1986) in both the validation and 
derivation cohorts. Evidence from this study may seem compelling because of the 
large numbers analysed and because the system derived is simple and easy to use. 
However there was only a statistically significant difference in the cardiac event rate 
between classes two and three in the validation cohort; although the relative risks 
between classes one and two ( 2.2), and three and four (1.7) did show a trend to better 
prediction of outcome. Inclusion criteria for the study were also vague with patients 
being included if they had prospectively consented to the study, but also if they 
underwent post-operative cardiac marker sampling. This latter group which 
represented 14.5% of the population was found to have a significantly higher 
morbidity and this could have led to potential selection bias. High risk of procedure is 
also used as a variable in the revised cardiac index despite no information being 
available on how the group was derived. Furthermore, intra-peritoneal procedures are 
included in the high risk group despite the fact that on separate analysis abdominal 
operations carried a relative risk of 0.8. The model also performed poorly for aortic 
aneurysm procedures with patients in category 2 having a higher risk of cardiac event 
than those in category 3. Although the index has a good negative predictive ability, 
only 10% of patients in the highest risk category had an event leading to a significant 
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number of false positives. It would not be feasible for all these patients to have their 
operative plan modified.  
 
Nevertheless, other investigators have found the revised cardiac risk index to have 
significant discriminatory ability (Boersma et al. 2001;Filipovic et al. 2003). Boersma 
et al (2001) retrospectively studied 1351 patients scheduled for vascular surgery. 
Some 611 patients had a score of 1, of whom 1.3% suffered an event. 509 had a score 
of 2, and 231 had scores of 3 or more with event rates of 3.1% and 9.1% respectively. 
Filipovic et al  (2003) also found RCRI measurement to be useful in their study of 
peri-operative risk, with a score of 4 being an independent predictor of outcome.   
 
The POSSUM scoring system was developed in 1991 and has been proposed as a tool 
for risk adjustment and comparative audit. It was developed from a multivariate 
discriminant analysis of factors measured in a broad group of general surgical patients 
(Copeland et al. 1991). It has been validated for use in general surgery but has been 
found to over-predict mortality, particularly in low risk groups (Whiteley et al. 1996). 
To address this, a revised equation for predicting death, the P-POSSUM was 
developed. This was shown to be a more accurate predictor of death (Whiteley et al. 
1996) and has been validated in vascular, as well as in general surgical patients. 
Midwinter et al (1999) evaluated the predictive value of P-POSSUM in a population 
of 221 vascular surgical patients. They concluded that the methodology allowed 
satisfactory prediction of morbidity and mortality since there was no statistically 
significant difference between the predicted and observed morbidity and mortality. 
However given the small numbers analysed, the observed differences were large in 
some groups. For example in the 15 patients judged to have an estimated risk of death 
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of 20-40% P-POSSUM predicted 4 deaths and none were observed. In fact, in 5 of the 
6 groups, P-POSSUM over predicted mortality albeit to a lesser extent than would 
have the original POSSUM equation. Although more useful than POSSUM it cannot 
be said that P-POSSUM is an accurate predictor of mortality as claimed. The lack of 
significant statistical difference between predicted and actual events in this study is 
likely to reflect a type 2 error.  Moreover as P-POSSUM requires operative 
information to calculate a score it cannot be used in pre-operative risk stratification. 
 
1.3.5 Serum Biochemical markers 
Several biochemical markers have been proposed as potential predictors of peri-
operative cardiac morbidity and thus as identifiers of patients at high risk. One such 
marker is cardiac troponin I (cTnI), a contractile protein which is released into the 
circulation after myocardial cell injury. It is not found in skeletal muscle and is 
therefore a sensitive and specific marker of myocardial necrosis and cardiac events 
(Adams, III et al. 1993;Apple et al. 1997). Hobbs et al (2005)  have shown that as 
many as 38% of patients undergoing lower limb revascularisation for critical limb 
ischaemia have a raised cTnI  post-operatively thus exhibiting myocardial injury. In 
this study of 29 patients there was no association between a raised post-operative cTnI 
and the late incidence of cardiac morbidity; however two patients with a raised pre-
operative cTnI were identified. Although these patients were excluded from analyses, 
both were followed up and found to have post-operative morbidity and mortality 
(cardiac event and death). 
 
Higham et al (2004) prospectively studied patients undergoing major vascular surgery 
or joint arthroplasty and demonstrated that an increase in peri-operative cTnI levels 
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was a significant predictor of adverse cardiac outcome at  both 1 month and 1 year. Of 
12 patients with a raised peri-operative troponin, 7 suffered a cardiac event post-
operatively.  The methods for the study were clear with well defined end points. A 
power calculation was used to determine the population size and the researchers 
would appear to have been blinded to troponin results although this is not clearly 
stated. However the significance of the conclusions is questionable as it is self-
fulfilling that a raised peri-operative serum cTnI should predict short term events 
given that myocardial infarction (partly defined by a raised cTnI) was one of the study 
end points. Cerebrovascular accident (CVA) was also used as an end-point in the 
study despite carotid endarterectomy patients being included. In this case the surgery 
itself and not any factor predicted by a raised troponin may be responsible for the 
adverse event. Although there was a four-fold increase in cardiac mortality at 1 year 
in those patients who had raised post-operative cardiac enzymes, no single cardiac 
enzyme was a significant predictor of this, the only objective outcome. Furthermore 
the association between the raised enzymes and 1-year cardiac mortality is almost 
certainly accounted for by those patients who had early cardiac events as no patients 
developing late complications had a raised post-operative cTnI.  
 
Kertai et al (2004) retrospectively studied the significance of cardiac troponin T 
(cTnT) measurement in 393 patients who had undergone aortic or infra-inguinal 
vascular surgery with a median follow up of four years. They excluded patients who 
had a confirmed myocardial infarction or cardiac death within 30 days of operation. 
They showed that an asymptomatic rise in cTnT peri-operatively was prognostically 
significant for all-cause mortality in the long term. A rise in cTnT was associated with 
an almost two-fold increased risk of mortality. The relationship remained significant 
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in multivariate analysis after correction for clinical and electrocardiographic findings. 
However, although the use of all-cause mortality as the primary end point prevents 
misclassification into cardiac or non-cardiac deaths, it leads to overestimation of the 
relevant end point, in this case cardiac complications. In addition, although only 
vascular procedures were included in the study, the population was heterogeneous 
since it contained patients undergoing both elective and emergency surgery. This was 
not accounted for in multivariate analyses. Furthermore, physicians had access to the 
cTnT results during the study which could have led to a treatment bias. 
 
Kim et al (2002)  prospectively studied cTnI levels in 229 patients post vascular 
surgery. CTnI levels were measured immediately after surgery and on the first three 
post-operative days. Clinicians were blinded to results. 98 patients had a detectable 
cTnI (>1.5ng/ml). The mortality at 6 months was 8%.  A raised post-operative cTnI 
was an independently significant predictor of all-cause mortality with the difference 
first becoming apparent at 6 weeks. Mortality was higher in those patients with a 
greater cTnI rise: patients with an undetectable troponin had an odds ratio for death of 
1.3, compared with 4.3 and 4.9 for patients with cTnI concentrations between 0.4 and 
1.5mg/ml, and 1.6 and 3mg/ml respectively. However the study failed to exclude from 
analysis the 8 patients who had suffered a post-operative MI. The inclusion of these 
patients may have led to an overestimation of the influence of an isolated troponin rise 
with their mortality being secondary to the peri-operative MI. In addition no attempt 
was made to differentiate the cause of mortality in analyses and no account was taken 
of the stress of the procedure as a possible confounding factor. 
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A rise in peri-operative troponin would appear to be a prognostic indicator and its 
routine analysis may be of use to identify a high risk sub-group who would benefit 
from more intensive post operative care and follow up. A randomised study to assess 
any benefit from this may be beneficial.  
 
D-dimer levels have been shown to correlate with the risk of coronary events in 
patients with peripheral arterial disease (Fowkes et al. 1993) and in 2001 Mamode et 
al (2001) found d-dimer levels to be a significant univariate and multivariate predictor 
of adverse cardiac events with odds ratios of 3.17 and 3.23 respectively. D-dimer 
level gave additional information to clinical assessment alone. However when only 
the objective end points of MI and cardiac death were considered, d-dimer level was 
no longer predictive of outcome. Furthermore there were weaknesses in the study 
design. Of a potential cohort of 608 patients undergoing surgery, only 297 were 
recruited raising the possibility of selection bias. In addition, results of pre-operative 
tests were available to clinicians, which in 19 cases led to the treatment plan being 
changed. This may have resulted in treatment bias and a possible reduction in the 
event rate. No researchers have provided further information on the prognostic value 
of d-dimers since this study’s publication.  
 
Evidence is accumulating that atherosclerosis is an inflammatory process (Libby 
2002;Willerson & Ridker 2004) and raised circulating concentrations of the non-
specific acute phase reactant c-reactive protein (CRP) have been shown to predict the 
occurrence of coronary events in patients with stable and unstable angina (Haverkate 
et al. 1997). In the Honolulu Heart Study patients with a raised CRP had increased 
odds of suffering an MI not only in the first few months of follow-up but as far as 20 
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years in the future (Sakkinen et al. 2002). Thus CRP concentration can predict cardiac 
outcome in the short and long term. CRP levels are also associated with the likelihood 
of developing peripheral vascular disease (Ridker et al. 1998) and show an inverse 
relationship with the ankle-brachial pressure index (Vainas et al. 2005).  
  
Rossi et al (2002) found c-reactive protein (CRP) concentration to be an independent 
predictor of myocardial infarction in post-operative peripheral vascular disease 
patients. CRP levels in the upper tertiles predicted 60% of myocardial infarctions at 
24 months. However only 51 patients were studied, 39 of whom underwent an 
endovascular procedure. Given that 1 patient underwent aortic bypass surgery this 
makes the population extremely heterogeneous in terms of operative stress. Despite 
this, the remainder of the study had a very exclusive design. Some 119 patients were 
excluded because of high baseline cardiac risk or the presence of infective, 
inflammatory or neoplastic disease. Even so, the cardiac event rate of 34% was high. 
When analysed, CRP concentration was only found to be predictive of MI at 24 
months and not at 30 days. This is surprising given that it is an acute phase 
inflammatory marker. However this may be due to type 2 error as only one major 
event had occurred at a month. Alternatively it is possible that the surgery conducted 
was irrelevant and that CRP is instead a marker of base-line risk.  
 
In a prospective observational study of 259 patients with critical limb ischaemia 
Barani et al (2005) found that raised inflammatory markers were associated with 
increased 1-year mortality. In the 61 patients who died, the mean CRP (mg/l) was 
49.4 (+/-62.1) compared with 33.6(+/-56.5) in survivors. (p=0.02). However when the 
presence or absence of gangrene was taken into account the difference was no longer 
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statistically significant, suggesting that peripheral inflammation rather than 
generalised atherosclerosis accounted for the difference. However, levels of other 
markers of inflammation such as TNF, and IL-6 did remain significant predictors of 
outcome after logistic regression accounting for the presence of gangrene. Outcome 
was not significantly affected by surgical intervention although there was a trend to 
poorer prognosis in those patients who did not receive operative treatment. 
 
Vainas et al (2005) conducted a study hypothesising that CRP was not only a marker 
of atherogenesis but actively participated in the process. Using reverse transcription–
polymerase chain reaction analysis they showed that CRP was produced by, and 
found in femoral plaques but not in healthy brachial arteries. This particular study also 
analysed the association between CRP and various outcome measures. Some 136 of 
the 387 patients fulfilled the combined end-point of cardiovascular event (cerebral, 
coronary, peripheral) or death. Although CRP concentrations in the upper tertiles 
were not associated with any single end-point they were significantly associated with 
this combined end-point (p=0.02 using chi squared test for trend). CRP was also 
inversely associated with the ABPI. The study had an exclusive design with all 
patients having a CRP of greater than 10mg/l being excluded. However the 
association between CRP concentration and individual end-points was poor. In fact, 
patients with an intermediate CRP were more likely to suffer a coronary (12 vs.10) or 
peripheral (28 vs. 25) event. In addition there was only one more combined event in 
the high CRP group compared with the intermediate group (52 vs. 51). The novel 
finding that CRP is produced by femoral plaques is however noteworthy. 
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1.3.6 Transthoracic echocardiography (TTE) and resting left ventricular ejection 
fraction 
TTE is commonly used in pre-operative cardiac risk assessment. It can deliver 
information on global and regional ventricular function as well as valvular 
abnormalities, and avoids the need for intravenous injections or exposure to radiation. 
It has been found to provide independent information about the risk of post-operative 
cardiac complications (Rohde et al. 2001) although the extent of its predictive ability 
has varied between studies. Halm et al (1996) studied a prospective cohort of 339 
male veterans who underwent echocardiography prior to non-cardiac surgery. 
Clinicians were blinded to TTE results and patients were screened post-operatively 
for cardiac events. The best performing cut-off was a left ventricular ejection fraction 
(LVEF) of less than 40%. Some 65 patients had an adverse cardiac outcome and an 
LVEF of less than 40% was a significant predictor of cardiac events which were three 
times more likely in this group. However, the outcome measures of congestive cardiac 
failure (CCF) and in particular ventricular tachycardia (commonly unsustained) were 
subjective and of questionable clinical relevance. There were 10 ischaemic events 
(cardiac death, MI and unstable angina) and no echocardiographic measurement was 
predictive of these, the most objective and clinically important outcomes. On further 
analysis, adding echocardiographic variables to existing clinical models led to an 
improvement in positive predictive value (50%-73%) but no change in the negative 
predictive value for all cardiac events.  
 
Other investigators have had similar results. McEnroe et al (1990) studied 59 patients 
undergoing abdominal aortic aneurysm repair. In this retrospective study all post 
operative ischaemic events occurred in patients with an ejection fraction of greater 
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than 50%. Takase et al (1993) studied 53 patients undergoing non-vascular surgery. 
Although reduced ejection fraction was predictive of peri-operative pulmonary 
oedema, it was not of benefit in the detection of myocardial infarction or cardiac 
death. Mamode et al (2001) also found ejection fraction to be a poor predictor of 
cardiac outcome in their study of 297 patients. More recently, in their study of 207 
patients scheduled for aortic aneurysm surgery, Crow and colleagues found that 
reduced left-ventricular ejection fraction did not correlate with cardiac morbidity or 
mortality (Crow et al. 2004). The study also demonstrated that measurement of 
ejection fraction did not influence the decision of whether or not to proceed with the 
proposed surgery as in only one patient was the management plan altered as a result 
of TTE results. 
 
In contrast some authors have found TTE to be a useful tool in predicting peri-
operative cardiac risk. In 2001 Rohde et al (2001) studied 570 patients who had 
undergone TTE within three months of major non-cardiac surgery. The collection of 
pre-operative information and analysis of post-operative clinical data was conducted 
prospectively by clinicians blinded to echocardiographic data, however the 
information derived from echocardiography was retrospectively abstracted from 
letters sent to general practitioners. There were multiple study end-points (MI, 
pulmonary oedema, ventricular fibrillation, cardiopulmonary arrest, complete heart 
block) for which screening was conducted. The authors found that documentation of 
systolic dysfunction was a significant predictor of both MI and pulmonary oedema. In 
addition, systolic dysfunction and moderate to severe left ventricular hypertrophy 
were independent predictors of major cardiac events. Risk assessment models which 
included TTE data performed significantly better than those containing clinical 
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information alone (area under ROC curve, 0.73 vs. 0.68; p<0.05). However, although 
the presence of TTE-detected left ventricular systolic dysfunction had a negative 
predictive value (NPV) of 94% it only had a positive predictive value (PPV) of 13%. 
There were other limitations in the study protocol: TTE data may have been 
unreliable due to the retrospective data collection and source; the study population 
was highly selected (those patients in whom a pre-operative echo had been deemed 
clinically necessary); and treating clinicians had access to TTE data which could have 
resulted in treatment bias.  
 
Kontos et al (1996) prospectively studied 87 patients who underwent TTE prior to 
major non-cardiac surgery. An ejection fraction of less than 50% had a PPV of 43% 
and an NPV of 97% for cardiac events, outperforming dipyridamole thallium 
scanning (DTS) which was also analysed in this study. In multivariate analysis a 
reduced ejection fraction was the only significant predictor of events. Despite the fact 
that the numbers analysed in this study were small, the population was highly selected 
and although clinicians were not blinded to TTE results, the study was well designed. 
It was prospective, the end points (MI, cardiac death, pre-operative revascularisation) 
were objective and post-operative screening was conducted. Rossi et al (1998) have 
also found reduced LVEF to be significantly predictive of early and late cardiac 
events. In this study a reduced LVEF had a PPV of 26% and an NPV of 93% for early 
cardiac events. However these results are difficult to interpret due to the small 
numbers involved (n= 97), the fact that the majority of patients did not undergo an 
open surgical procedure (73% underwent an endovascular procedure), and poor 
definition of end-points, which included myocardial ischaemia, pulmonary oedema 
and ventricular tachyarrhythmias.  
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1.3.7 Cardiac stress testing 
In an effort to recreate the physiological burden placed on the body by surgery, 
cardiac stress testing has been utilized in peri-operative risk stratification. 
Dipyridamole-thallium scintigraphy (DTS) and dobutamine stress echocardiography 
(DSE) are the methods most commonly used. 
 
Dipyridamole thallium scanning 
DTS involves artificially increasing myocardial perfusion using dipyridamole, 
followed by thallium imaging which allows defects in the myocardial image to be 
detected. Reversible defects (those not present at rest) indicate myocardium at risk of 
ischaemia. Eagle et al (1989) were among the first to analyse its potential. They 
studied 200 patients referred to a nuclear cardiology unit prior to vascular surgery and 
found a reversible perfusion defect to be a significant predictor of the combined end 
point of cardiac death and MI. Thirteen of the 15 patients who suffered a post-
operative MI or cardiac death had a positive thallium scan.  The test was most 
discriminatory in the group considered at moderate risk clinically (those fulfilling 1 or 
2 of Eagle’s clinical variables). Flaws in the study included both referral and 
treatment bias. The population was highly selected and study results were available to 
treating physicians. Some 44 patients had their surgery either cancelled or postponed 
following evaluation. Although the end points considered were objective, the 
definition of cardiac death was non-specific, defined as any sudden post-operative 
death. More recently Mamode et al (2001) have found DTS to be an accurate 
predictor of cardiac events adding significant discriminatory information to clinical 
data alone. Although their study of 297 vascular surgical patients was flawed (with 
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the inclusion of non-consecutive patients and lack of blinding to DTS data) it showed 
after multivariate analysis that a reversible defect on DTS had an odds ratio (OR) of 
13.6 (3.7-50.8) for the fulfilment of the combined end point of cardiac death and 
myocardial infarction. The test also had a sensitivity of 38% for the prediction of 
cardiac events. 
 
Mangano et al (1991) conducted a study of 60 vascular surgical patients who had 
undergone DTS. They did not find any correlation between a perfusion defect on DTS 
and adverse outcome, and 7 of the 13 post-operative events occurred in patients with 
no perfusion defect. The study was prospective, triple blinded and the end points were 
clearly defined and objective. However it suffered from small numbers with only 60 
patients and 13 adverse events. Consecutive patients were enrolled but the study 
design was highly exclusive with patients having unstable heart disease, pacemakers 
or ECG abnormalities being excluded. 
 
Baron et al (1994) studied a cohort of 457 patients undergoing abdominal aortic 
surgery. They found that DTS was of little benefit in predicting peri-operative cardiac 
morbidity and that a definite history of ischaemic heart disease and age over 65 were 
the most important predictors of an event. A reversible perfusion defect on DTS was 
not a predictor of any cardiac event by either univariate or multivariate analysis, and 
only 31 of the 160 patients with a reversible perfusion defect experienced a post-
operative cardiac event. Consecutive patients were enrolled; however clinicians were 
not blinded to DTS results with a consequent potential treatment bias. Although 
ventricular tachyarrhythmias and prolonged myocardial ischaemia were considered in 
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the combined end point, more objective end points such as cardiac death were 
analysed separately and also found not to correlate with DTS data. 
 
Shaw et al (1996) conducted a systematic review of published reports on 
dipyridamole thallium scanning in the 10 years from 1985. Ten studies of appropriate 
quality were identified giving a total population of 1994 vascular surgery patients. 
Using the objective end points of cardiac death and MI, 1% of patients with no 
perfusion defect had an event compared with 9% of patients who had a reversible 
defect. This difference was statistically significant. The OR for prediction of a cardiac 
event was 3.9. Five studies included in the review utilised multivariate analysis and 
showed a reversible perfusion defect on DTS to be the single best predictor of events. 
However, only 4 of the studies were blinded which led to 6% of patients having 
surgery cancelled, 20% undergoing coronary angiography and 5% of patients 
undergoing pre-operative coronary revascularisation. The influence of publication 
bias may also have contributed to the number of papers citing positive results.  
 
More recently, imaging has been performed using technetium-99m single photon 
emission computed tomography (SPECT) following dipyridamole infusion. Cohen et 
al (2003) retrospectively analysed its predictive potential in 153 patients undergoing 
elective vascular surgery. There were 16 post-operative events, and whilst none of 
these occurred in patients with a normal scan, neither fixed nor reversible defects 
were significantly predictive of outcome. In fact, no increased risk was conferred by 
the presence of a reversible defect (RR=1). However the study was limited by lack of 
blinding, poor definition of end-points, and a low event rate. Nine patients underwent 
coronary angiography and 1 proceeded to coronary angioplasty prior to surgery as a 
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result of SPECT data. Unstable angina and heart failure were used as end points and 
there was no differentiation of cardiac and non-cardiac death.  
 
Dobutamine stress echocardiography (DSE) 
In DSE, dobutamine is used to increase myocardial oxygen consumption, “stressing” 
the heart. The heart is imaged using TTE before and after the stress with wall motion 
defects being recorded. New wall motion abnormalities (NWMAs) indicate 
myocardium at risk of infarction. DSE is accurate in the detection of significant 
coronary artery disease (Cohen et al. 1991;Sawada et al. 1991) and has been 
advocated as a useful technique for pre-operative risk stratification. However it is 
expensive (although less so than thallium scanning), time-consuming and is not 
universally available in the United Kingdom.  
 
Poldermans et al (1993) studied 131 consecutive patients undergoing vascular surgery 
and found DSE to be a practical and safe method of stratifying cardiac risk. It had an 
NPV of 100% and a PPV of 42% for the detection of cardiac events. Inducible 
ischaemia on DSE, and age over 70 were the only 2 independent predictors of an 
event. The study was prospective and blinded, however 10 of the 15 post-operative 
cardiac complications were subjective in definition (CCF and unstable angina). In an 
extension of this study published in 1995 involving a population of 302 patients, the 
value of DSE was further emphasised (Poldermans et al. 1995). All 27 patients 
suffering a cardiac event had NWMAs on TTE. A positive result on DSE had an OR 
of 124 and was the only factor found to be a significant predictor of post-operative 
cardiac events on multivariate analysis. The PPV was 38%. Interestingly neither 
ventricular dysrhythmias nor CCF were employed as end points in this study and a 
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greater proportion of patients (17 of 27) fulfilled the objective end points of cardiac 
death and non fatal MI.  
 
Das et al (2000) retrospectively studied 530 patients having non-vascular surgery who 
had previously undergone DSE without subsequent intervention. Inducible ischaemia 
had an NPV of 100% and a PPV of 15% for a cardiac event. An ischaemic threshold 
of less than 60% of age-predicted maximum heart rate added discriminatory 
information. DSE data provided incremental risk prediction at each level of the 
clinically based (Eagle’s index) risk assessment. Although the end points in this study 
(non fatal MI and cardiac death) were objective, the study suffered from selection bias 
with the inclusion of only those patients thought to require DSE on clinical grounds. 
This resulted in an exceptionally high risk group, 30% of whom had suffered an MI in 
the past and only 29% of whom had a normal pre-operative ECG. There was no 
blinding; therefore treatment bias may have influenced results. In addition patients 
who had undergone coronary revascularisation as a result of a positive test were 
excluded from the retrospective analysis. Furthermore, post-operative screening for 
cardiac events was inconsistent with only 60% of patients undergoing routine testing 
following surgery. 
 
In 1998, in their study of 103 patients undergoing lower limb revascularisation, Rossi 
et al (1998) found that combining resting and stress echocardiography achieved a 
NPV of 100% for the detection of cardiac events The PPV was 25%. Stress 
echocardiography alone had an NPV of 94% and a PPV of 25%. Reduced LVEF and 
positive stress echocardiography were the only significant predictors of peri-operative 
cardiac events. However 73% of patients in the study underwent endovascular 
 49 
procedures and so were at low risk of peri-operative cardiac events. In addition only 
two patients fulfilled the objective end-points of cardiac death or MI; the remainder of 
the linked events being CCF, myocardial ischaemia and tachyarrhythmias; subjective 
end-points which were not defined and of limited prognostic significance. A 
continuous cohort of patients was not studied and physicians were not blinded to 
research data. 
 
Boersma et al (2001) studied a cohort of 1351 patients undergoing major vascular 
surgery. Some 1097 underwent DSE preoperatively and 360 received beta blocker 
therapy. There were 31 cardiac deaths and 14 non-fatal MI’s. The presence of 
NWMAs on DSE was predictive of peri-operative cardiac events (13.5% vs. 1.6%) 
and the extent of stress-induced ischaemia also added prognostic information. In 
multivariate analysis, the presence of NWMAs was the most important predictor of 
cardiac events. DSE data significantly improved the predictive ability of clinical data 
alone but were of most help in patients with a RCRI score of greater than 3. The study 
was well designed with objective end points and clear methodology but was limited 
by its retrospective nature; nonetheless it provides strong evidence supporting the use 
of DSE in peri-operative cardiac risk stratification. Kertai et al (2003b) later studied 
the same cohort of patients and showed that dobutamine-induced ischaemia was a 
significant predictor of late cardiac complications. In this retrospective study of the 
1286 patients who had survived 30 days post-operatively after vascular surgery, 
15.5% of patients with stress induced ischaemia suffered a cardiac event compared to 
4.9% of those without. In multivariate analysis the presence of stress-induced 
ischaemia proved to be the most important factor in predicting cardiac events. 
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Furthermore the greater the extent of the stress- induced ischaemia the greater the 
likelihood there was of a cardiac event. 
 
Pathological studies have analysed the usefulness of DSE. Poldermans et al (2001) 
studied 32 patients who died within 30 days of vascular surgery having undergone 
DSE prior to the procedure. Only 17 patients were suspected of having died from a 
cardiac cause yet autopsy showed evidence of recent MI in 21, 9 of whom had 
evidence of infarction in more than 1 coronary artery territory. All 16 patients who 
had a positive pre-operative DSE suffered a death confirmed to be of cardiac origin. 
However DSE would have failed to identify the remaining 5 patients with acute MI 
confirmed on autopsy. In addition 9 of the 16 patients had evidence of infarct in an 
area not shown to have NWMAs at DSE. 
 
In meta-analysis DSE has outperformed 5 other diagnostic tests (ambulatory 
electrocardiography, exercise electrocardiography, radionuclide ventriculography, 
myocardial perfusion scintigraphy, dipyridamole stress echocardiograph) in predicting 
cardiac events, although the difference was only significant over DTS (Kertai et al. 
2003a). Some 8119 patients participated in the studies selected and the comparison 
between tests took account of differing study and clinical characteristics. 
 
The subgroup of patients in whom DSE and other pre-operative investigations should 
be used remains uncertain. To address this, the American College of Cardiology and 
the American Heart Association produced an algorithm for the use of DSE in peri-
operative risk stratification (Eagle et al. 1996). The guidelines have been widely 
endorsed despite the fact that there was inadequate data in the literature to support 
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many of the recommendations. More recently the cost-effectiveness of the use of DSE 
according to these guidelines has been questioned. Morgan et al (2002) reviewed 
some 14855 patients scheduled for elective surgery. The guidelines led to 85 of these 
patients undergoing DSE. The positive predictive value for selecting a positive DSE 
was only 4.7 % and none of these patients suffered any cardiac morbidity. This would 
suggest that the appropriate place for DSE in peri-operative assessment is still 
unknown, a conclusion supported by other studies which have found that the 
ACC/AHA guidelines overestimate the requirement for cardiac investigation (Falcone 
et al. 2003;Farid et al. 2002).  
 
However, appropriate use of the guidelines has been shown to be of benefit in peri-
operative assessment. Back et al (2003) studied 425 consecutive vascular patients. 
Using the ACC/AHA guidelines, 200 patients underwent cardiac stress imaging 
leading to 78 patients undergoing coronary angiography. 15 patients underwent 
subsequent coronary intervention. Based on the results of the above investigations and 
interventions, the patients were placed into appropriate risk categories. The overall 
cardiac event rate was low (4.8%) at 30 days and those patients judged to be at high 
risk by the guidelines had a significantly higher event rate  (11.9%) than those placed 
into lower risk categories (2.8% and 4%). The guidelines however were unable to 
differentiate between patients in the low (4% event rate) and intermediate (2.8% event 
rate) risk categories. The methodology of the study was clear and consecutive patients 
were enrolled. However multiple subjective end points (unstable angina, heart failure, 
arrhythmias) of limited prognostic value were studied. Despite this the study does 
show that a low event rate can be achieved in a relatively high risk population using 
the guidelines. However many patients underwent unnecessary investigation in the 
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process, again suggesting that the role of DSE in pre-operative assessment remains 
unclear.  
 
Cardiopulmonary exercise testing 
Cardiopulmonary exercise testing (CPX) is a non-invasive test used for the 
assessment of cardiac and respiratory function. It measures oxygen uptake at 
increasing intensities of work and objectively determines cardiopulmonary 
performance. It is normally performed on a bicycle ergometer using respiratory gas 
analysis and an electrocardiogram. Both the exercise anaerobic threshold and the 
ventilatory equivalent for carbon dioxide (VE/VCO2) can be determined at 
cardiopulmonary exercise testing.  
 
In 2 separate studies Older et al. have demonstrated that an exercise anaerobic 
threshold of less than 11 ml/min/kg significantly predicts postoperative survival 
(Older et al. 1993;Older, Hall, & Hader 1999). The most recent publication, studied 
548 patients undergoing major intra-abdominal surgery. Nine patients died of 
cardiopulmonary causes post-operatively and of these 7 had an anaerobic threshold of 
less than 11ml/min/kg.  
 
Carlisle et al. evaluated CPX in 130 patients who underwent abdominal aortic 
aneurysm repair (Carlisle & Swart 2007). They demonstrated that both VE/VCO2 and 
anaerobic threshold were significantly predictive of long-term survival. At a median 
follow-up of 33 months, survival was 55 per cent for the 30 patients judged unfit by 
CPX, compared with 97 per cent for the 100 patients judged fit (P < 0.001). 
 
 53 
However CPX is unsuitable for patients with critical limb ischaemia in whom 
claudication is likely to limit exercise capacity. Patients whose surgery is urgent 
rather than elective would also be unlikely to be able to access CPX due to logistics. 
Furthermore CPX has not proven beneficial in predicting post-operative 
cardiopulmonary morbidity in procedures such as oesophagectomy (Forshaw et al. 
2008). 
 
1.4 Preventing peri-operative cardiac morbidity: the benefit of perioperative risk 
stratification 
The assignment of patients to different categories of peri-operative cardiac risk may 
be of benefit. Patients judged to be at low risk can have their surgery expedited with 
no requirement for further time-consuming or costly investigations. If patients are 
judged to be at high risk, various options exist. In some cases postponement or 
cancellation of the procedure may be appropriate. For example it may be 
inappropriate to operate on a 5.5cm aortic aneurysm in an elderly gentleman with 
unstable angina. However, in some cases, surgery may be deemed necessary. In this 
event, efforts should be directed at reducing the associated perceived cardiac risk. 
This could involve alterations in the pre-, intra- or post-operative management. Pre-
operative coronary intervention (Eagle et al. 1997) and prescription of appropriate 
cardiac medications (Poldermans et al. 1999) have both been shown to influence 
cardiac risk. Anaesthetic techniques such as the use of thoracic epidurals can reduce 
morbidity (Beattie et al. 2003). In some cases it may even be possible to perform a 
surgical procedure with lower associated risk. Post-operatively, increased intensity of 
care such as in a high dependency unit might also be of benefit. 
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1.4.1 Coronary Revascularisation 
Pre-operative coronary revascularisation can be conducted using both open and 
percutaneous methods. It may be done prophylactically or in selected patients. 
Eagle et al (1997) retrospectively studied 3368 patients who had undergone non-
cardiac surgery in the Coronary Artery Surgery Study registry. Patients in this 
population had documented coronary artery disease and had received either best 
medical treatment or coronary revascularisation depending on physician and patient 
preference. Some 1961 patients who had undergone a high risk surgical procedure 
were included. Coronary revascularisation prior to surgery significantly reduced the 
rate of MI (0.8% vs. 2.7%) and of death (1.7% vs. 3.3%). Patients with more severe 
coronary disease were shown to derive most benefit. The effect of coronary surgery 
was maintained after adjustment for other risk factors with an OR of 2.5 (1.41-4.46).  
However, recruitment for the study began in 1974 so its applicability to present 
practice is questionable. In addition the demographics of the two groups were not 
compared and patients were not randomised to medical therapy or surgery. The main 
failing of the study however was its failure to take into account intention to treat. 
Cardiac surgery has significant morbidity and patients who suffered any complication 
of this surgery were invariably excluded from the analysis.   
 
Fleischer et al (1999) studied a retrospective cohort of 6895 patients undergoing 
elective vascular surgery. In the subgroup of 2865 patients undergoing aortic surgery 
it was found that those who had undergone stress testing, with or without coronary 
revascularisation had significantly lower 30 day mortality (3.8% vs. 9%). Patients 
who had undergone coronary revascularisation following stress testing had the lowest 
peri-operative mortality (2.8%), although unfortunately no information was available 
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on mortality from the coronary artery revascularisation itself. Neither stress testing 
nor pre-operative revascularisation affected the peri-operative mortality in those 
patients undergoing infrainguinal procedures. Limitations of the study include the 
high overall 30 day mortality of 7.3%, disregard for potential clinical confounding 
factors and the retrospective nature which led to problems with data retrieval. In 
addition, no attempt was made to differentiate between cardiac and noncardiac causes 
of death. 
 
Landesberg et al (2003) examined the efficacy of non-invasive testing and subsequent 
coronary revascularisation in patients undergoing major vascular surgery. All 407 
patients included had undergone DTS preoperatively and patients with moderate –
severe reversible defects or at high clinical risk were referred for coronary 
angiography and subsequent percutaneous transluminal coronary angioplasty (PTCA) 
or coronary artery bypass grafting (CABG) as appropriate. For analysis, patients were 
placed into four groups: those with no defects or mild defects; those with fixed 
defects; those with reversible defects who did not undergo revascularisation and those 
with reversible defects who did undergo revascularisation. Patients who suffered 
morbidity from coronary revascularisation but did not undergo surgery were included 
in the final group. Patients were followed up for a period of 55 months (18-138). The 
presence of a moderate to severe reversible perfusion defect on DTS predicted poorer 
survival rates. Pre-operative coronary revascularisation independently improved long 
term survival, although the difference did not become significant until 5 years follow-
up. Five year survival was 38% in those patients with reversible perfusion defects 
who had not undergone revascularisation compared with 62% in those who had.  
There was a trend towards better survival in the 36 patients who underwent CABG 
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compared with the 38 undergoing PTCA. The principal limitation of the study was its 
retrospective nature. The decision to revascularise patients with reversible ischaemia 
was made on clinical grounds and it is likely that the factors making patients 
unsuitable for revascularisation, for example the need for urgent surgery, may have 
had some impact on the reduced 5-year survival. The authors attempted to 
compensate for this using propensity analyses and although there was no significant 
difference between the two groups, it should be noted that only background factors 
included in the study were accounted for, with neither the type nor the urgency of 
surgery included. 
 
In an attempt to clarify the issue of prophylactic coronary artery revascularisation a 
randomised controlled trial was conducted (McFalls et al. 2004). Patients scheduled 
for elective vascular surgery and judged to be at increased risk of a peri-operative 
cardiac event by a consultant cardiologist were referred for coronary angiography. 
Patients with coronary arteries suitable for intervention were randomised using a 
stratified process and underwent the planned vascular procedure with or without prior 
coronary revascularisation. Of the 258 patients assigned to coronary intervention, 99 
underwent CABG, and 141 underwent PTCA. Eighteen did not undergo preoperative 
revascularisation due to patient choice (9), the need for urgent vascular surgery (8), or 
illness (1). Nine of the 252 patients scheduled to undergo surgery with no 
revascularisation required coronary intervention due to unstable cardiac disease. 
Seven of these subsequently underwent vascular surgery. Pre-operative 
revascularisation led to a significant delay in vascular surgery and in this group there 
were 10 deaths prior to vascular surgery compared with only 1 in the no-
revascularisation group. There was no significant difference in the 30-day mortality, 
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or in the rate of peri-operative myocardial infarction of those patients who survived to 
undergo vascular surgery. At a median follow-up of 2.7 years, mortality in those 
patients assigned to revascularisation was 22% compared with 23% in those who were 
not. When actual treatment received was analysed, mortality was also 22% in the 
revascularisation group and 23% in the no-revascularisation group. The study was 
adequately powered and the end-points were objective. The committee validating all 
outcomes was blinded to coronary intervention. Although treating clinicians were not 
blinded, there were no obvious differences in peri-operative management. There were 
no significant differences in clinical variables between the groups; although 12% of 
those patients randomised to revascularisation had a previous history of heart failure 
compared with 7.5% of those who solely underwent vascular surgery. Heart failure is 
one of the most important predictors of peri-operative events and this difference may 
have influenced outcome. This however should not detract from the conclusion that 
prophylactic revascularisation showed no benefit prior to elective vascular surgery in 
this cohort of patients.   
 
1.4.2 Beta Blockers 
The beneficial role of beta blockers has previously been established in hypertension, 
acute coronary syndromes and heart failure, and it is believed that peri-operative beta-
blockade may reduce the cardiac morbidity associated with surgery. Beta blockers 
increase diastolic perfusion time and reduce cardiac oxygen demand by decreasing 
heart rate and contractility. They have potent anti-arrhythmic effects, particularly in 
the setting of acute ischaemia and have been shown to have an anaesthetic sparing 
effect. They may also influence atherosclerotic plaque instability by reducing shear 
stress (London et al. 2004;Ohtsuka et al. 2001).    
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In 1996 Mangano et al (1996) published the findings of a randomised, double-blinded 
controlled trial of patients at risk of coronary artery disease undergoing non-cardiac 
surgery which found that the peri-operative prescription of atenolol significantly 
reduced post-operative ischaemia and mortality. Two hundred patients were 
prospectively enrolled and at two year follow-up there were 21 deaths and 32 cardiac 
events in the placebo group compared with 12 deaths and 16 cardiac events in the 
atenolol group. Event-free survival throughout the two-year study period was 68 
percent in the placebo group and 83 percent in the atenolol group (P=0.008).  The 
protective effect principally came from a reduction of cardiac events in the first 6 
months after discharge. A statistician was consulted regarding numbers for the trial, 
the end-points were clear, and follow-up to two years was almost complete. However 
although the randomisation process was computerised, it was not stratified leading to 
some inequalities between group; for example the number of patients in the atenolol 
group prescribed anti-hypertensive agents was significantly greater than that in the 
placebo group suggesting that this group may have been better optimised. The 
incidence of definite coronary artery disease, previous MI and the presence of typical 
angina were also higher in the placebo group although not significantly so, making 
these patients more susceptible to cardiac morbidity. A further flaw was that those 6 
patients who died in hospital were excluded from analysis. Four of these occurred in 
the atenolol group and although only one was of cardiac origin, if these results are 
included, the difference in all-cause mortality between the groups would no longer 
reach statistical significance. In addition some 8 patients in the placebo group 
regularly took beta blockers. This may have influenced the results as the withdrawal 
of established beta-blocker therapy is likely to have compromised the patient’s 
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cardiac status. Nevertheless there was a 55% decrease in overall mortality and a 65% 
reduction in cardiac death in the atenolol group and this effect is unlikely to have 
solely been due to differences between the two populations, particularly as 
multivariate analysis revealed that the presence of diabetes and the prescription of 
atenolol were the only significant predictors of poor outcome. 
 
The other early randomised controlled trial of peri-operative beta-blockade, in this 
case with bisoprolol, was conducted by Poldermans et al (1999). Included were 112 
patients undergoing major vascular surgery with a positive result on DSE, and 
investigators found that those patients randomised to receive oral bisoprolol had a 
reduced peri-operative cardiac event rate. Some 35% of patients in the standard care 
group suffered either a cardiac death or a non fatal MI within 30 days of the procedure 
compared with 3.4 % in the bisoprolol group. Randomisation was carried out using a 
computer programme and this resulted in there being only minor differences between 
the groups. However the study design had some flaws: clinicians were not blinded to 
patients grouping; 4 patients in the placebo group received beta blockers; and the 
study was terminated after only 100 patients had been recruited despite an earlier 
power calculation recommending that 266 were required. The 35% event rate in the 
placebo group was also unusually high and the relevance of this highly selected study 
population to the general setting could be questioned. Despite these problems with the 
study protocol, the large difference in event rates would support the protective value 
of beta blockers suggested by Mangano and colleagues.  
 
Boersma et al (2001) retrospectively studied 1351 patients undergoing major vascular 
surgery, 360 of whom were prescribed beta blockers. Of these, 301 were on long term 
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beta blockers, with the remaining 59 having been randomised to receive treatment as 
part of an earlier study (Poldermans et al. 1999). Patients receiving beta blockers 
generally had a worse risk profile, significantly more having a history of hypertension 
and ischaemic heart disease. Despite this they had a significantly lower 30 day cardiac 
event rate, although exact figures for the whole cohort are not available. The 
protective effect of beta blockers was most apparent in patients with NWMAs on 
DSE, with those prescribed beta-blockers having a cardiac event rate of 4.7% 
compared with 31.5% in those not. Although a difference was also seen in low risk 
patients it was not as marked. Problems with this study included the heterogeneous 
population (patients randomised to treatment, and those previously receiving beta 
blockers were all included), failure to blind physicians to DSE data or beta blocker 
usage, and the definition of end points. Although only cardiac death and non-fatal MI 
were considered, the number of deaths of cardiac origin was probably overestimated 
as all fatalities were included unless there was explicit evidence of a non-cardiac 
cause. Kertai et al (2003b) studied the same cohort of patients, following up those 
1286 patients who had survived 30 days after vascular surgery to assess the long term 
benefits of beta blockade. In this group 370 (29%) patients received beta blockers. 
The median follow-up period was 23 months and patients receiving beta blockers had 
a marginally higher event rate than those not, although this was not significant. 
However the result may have been influenced by differences in clinical characteristics 
as patients on beta blockers had a greater incidence of ischaemic heart disease and of 
heart failure. In multivariate analysis, patients on beta blockers had a lower likelihood 
of events although again this was not significant. The only group of patients to have a 
significantly reduced cardiac event rate when prescribed beta blockers were those 
with stress-inducible ischaemia on DSE. However this observed influence could be 
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attributable to treatment bias as physicians were not blinded to beta blocker 
prescription. In fact patients on beta blockers received more intense follow-up being 
seen at clinic every 3 months for dosage monitoring. The study also had other 
problems with its methodology: 59 patients had been randomised to beta blockers 
whereas the remaining 301 were previously on long term treatment; 24 patients were 
only prescribed beta blockers post-operatively but were still included in the treatment 
group; and 12 patients who had undergone coronary revascularisation post-
operatively were also included despite this potential influence on outcome. In their 
study, Lee et al (1999) found that patients taking beta blockers on admission to 
hospital had a similar cardiac event rate to those not. Some 13 of 533 (2.4%) patients 
on beta blockers suffered a cardiac event compared with 43 of 2360 (1.8%) who were 
not. Although it was not analysed, it is likely that those patients prescribed beta 
blockers were more likely to have risk factors for coronary artery disease which may 
have influenced results. 
 
Stevens et al (2003) pooled data on eleven randomised-controlled trials assessing the 
myocardial protective effects of beta blockers in patients undergoing non-cardiac 
surgery. Inclusion criteria and strategy for literature review were clearly set out with 
the last search being conducted in November 2002. No data were analysed beyond a 
follow-up of 1 month after surgery. Beta blockers decreased ischaemic events during 
(7.6% vs. 20.2%), and after (15.2% vs. 27.9%) surgery. Their use reduced the risk of 
myocardial infarction (0.9% vs. 5.2%) and cardiac death (0.8% vs. 3.9%). There was 
a correlation between the pre-study prevalence of MI and the magnitude of risk 
reduction. However, the results were somewhat biased by the significant findings of a 
few papers. When the two studies involving the highest risk patients and highest event 
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rates were excluded, beta blockers no longer significantly reduced the risk of MI. 
When the study by Poldermans et al (1999) was excluded from the 8 studies reporting 
cardiac death, then the protective effect of beta blockers was also no longer 
significant. Bradycardia was the commonest adverse event related to beta blockers, 
occurring in 24.5% of treated patients compared with 9.1% of controls. Hypotension, 
atrio-ventricular block and pulmonary oedema were reported more frequently in 
patients on beta blockers but the differences were not significant. In quantitative 
terms, for every 100 patients prescribed beta blockers, 4 post-operative MIs and 3 
cardiac deaths were prevented. However the studies included were heterogeneous in 
quality and different beta blockers and treatment regimens were used. Length of 
maintenance of the therapy also varied. There may also have been a temporal effect 
due to the inclusion of studies conducted as early as 1980. This is important since 
methods of anaesthesia and detection of post-operative events have changed over this 
period. In addition there was no standard definition of end points between the studies.  
 
Despite the early evidence supporting the protective effects of beta blockers, there is 
still a reluctance to prescribe them in the peri-operative setting, as illustrated by a 
recent survey of Canadian anaesthetists (VanDenKerkhof et al. 2003). Although 95% 
of the 569 respondents were aware of the literature and 93% felt that beta blockers 
were of benefit in patients with CAD only 57% always or usually used beta blockers. 
The poor response rate (54%) and the selected study population (members of the 
Canadian Anaesthesiology Society) probably mean that actual figures are lower. In 
fact a recent meta-analysis has questioned the protective role of beta blockers, 
suggesting that the current evidence is too unreliable to allow any definite conclusions 
to be drawn (Devereaux et al. 2005). Despite this statement, the paper which included 
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data from 22 randomised control trials found a statistically significant beneficial 
relative risk of 0.44 (95% confidence interval 0.20 to 0.97) for the composite outcome 
of cardiovascular mortality, non-fatal myocardial infarction, and non-fatal cardiac 
arrest. No significant benefit was found for any individual end-point; however this 
could be attributed to the inclusion of all randomised controlled trials in non-cardiac 
surgery which led to an extremely heterogeneous population. Studies conducted as 
early as 1980 were included, as were those reporting on low risk populations such as 
those undergoing day case surgery or even dental extraction.  
 
1.4.4 Statins 
Inhibitors of the enzyme reductase of the hydroxymethylglutaryl-coenzyme A (HMG 
CoA) or “statins” decrease cardiac events and increase survival in patients with 
hypercholesterolaemia who have either established, or are at high risk for coronary 
artery disease (CAD). They are pleiotropic agents, which in addition to lowering 
cholesterol have a modulatory effect on endothelial function, inflammation and 
thrombosis (Vaughan et al. 2000). Poldermans et al (2003) performed a retrospective 
case-control study on 2816 patients undergoing major vascular surgery between 1991 
and 2000. Case patients were the 160 who had died in hospital following surgery. 
Two controls for each case were chosen, one of whom had been operated upon 
immediately prior to the case and one of whom was operated on afterwards. There 
was a significant difference in statin usage between groups. 12 (8%) of cases received 
statins preoperatively compared with 81 (25%) of controls and the adjusted odds ratio 
for comparison of mortality between the groups was 0.22 (95% confidence interval 
0.10-0.47). However, although the reduction in risk associated with statin use was 
maintained in sub-group analysis, confounding factors may have been responsible for 
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the significant difference noted as relevant clinical details such as a history of COPD 
were not included. In addition, beta blocker usage was significantly less common in 
cases than controls. This may be partly responsible for the case group’s poor outcome 
given the potential protective effects of beta blockers. The study was also 
retrospective and the potential for observer bias may limit the significance of its 
findings. 
 
Kertai et al (2004a) retrospectively studied 570 elective abdominal aortic aneurysm 
patients and found that the pre-operative prescription of statins independently reduced 
the risk of cardiac events and peri-operative mortality. Some 3.7% of patients 
prescribed statins had an event compared with 11% not prescribed the medication. 
The relationship was strongest in patients with a RCRI score of greater than two. 
Although the study was retrospective, researchers were blinded to outcome and 
multivariate analysis was conducted using the RCRI. However this does not take into 
account some of the important differences between the groups, for example, patients 
using statins were significantly younger and were more likely to have been prescribed 
other cardiac medications. Although they were also more likely to have suffered a 
previous MI, significantly more of the patients on statins had undergone prior 
coronary revascularisation. The effect of statins could therefore have been influenced 
by better pre-operative optimisation in these patients. In addition several different 
statins were used throughout the study and no information was available as to whether 
statin use had been continued throughout the peri-operative period.  
 
In a retrospective study of 997 patients undergoing vascular surgery, O’Neill-
Callaghan et al (2005) found that statins reduced the incidence of cardiac morbidity. 
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Some 9% of the 526 patients on statins had an event compared with 16.5% of patients 
not on statins (OR=0.56, p=0.001) and the propensity for a reduction in cardiac events 
remained after multivariate analysis. The study was well designed: a power 
calculation was used to determine the population size and there was quality control of 
the case-note review. However myocardial ischaemia, CCF and ventricular 
tachyarrhythmias were included as primary end points. When only objective end 
points such as death and acute MI were included, the benefit from statin usage was no 
longer statistically significant.  
 
One randomised trial has been conducted assessing the effects of statins (in this case 
atorvastatin) on the occurrence of a 6-month composite of cardiovascular events 
(cardiac death, non-fatal MI, unstable angina, stroke) following vascular surgery 
(Durazzo et al. 2004). The study was double blinded and its design exclusive with 127 
patients being judged ineligible. Some 50 patients were randomised to each group 
with 3 of those randomised to statin therapy being non-compliant. Data was analysed 
on an intention to treat basis. The atorvastatin group demonstrated a significantly 
lower cardiac event rate over the 6-month period with 4 events in this group compared 
with 13 in the placebo (p=0.022). There were no significant differences in the case-
mix of the 2 groups and although only 90 of the patients subsequently underwent 
surgery the event rate remained significantly lower if patients were prescribed 
atorvastatin. 
 
1.4.5 Method of Anaesthesia 
Anaesthetic technique may influence the cardiac risk associated with surgery. The use 
of epidural anaesthesia and analgesia is thought to reduce cardiac stress through 
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systemic and coronary vasodilatation and a consequent reduction in cardiac pre-load. 
The improved post-operative analgesia provided reduces post-operative stress and 
hypertension.  
 
Beattie et al (2003) conducted a meta-analysis investigating the effects of post-
operative epidural analgesia on cardiac event rates. Eleven randomised controlled 
trials comparing post-operative epidural analgesia with other forms of parenteral 
analgesia were identified up until December 1998. A total of 1173 patients 
undergoing a variety of peripheral vascular and intra-abdominal procedures were 
studied. The group of patients receiving epidural analgesia had a significantly lower 
rate of post-operative myocardial infarction with a difference of 3.8% (p=0.049). The 
epidural group also had fewer deaths (rate difference 1.3%) although the difference 
was not statistically significant. (p=0.091). Sub-group analysis of those patients 
receiving post-operative thoracic epidural analgesia showed a post-operative MI rate 
reduction of 5.3% (p=0.04). There were no statistically significant differences in co-
morbidity between groups; in fact more patients in the epidural group had a history of 
cardiac disease or COPD. However when a single study, that by Yeager et al (1987), 
is excluded the difference in peri-operative myocardial infarction between the groups 
is no longer significant although there remains a trend to a decrease in MI. The study 
by Yeager et al was terminated early because of the magnitude of the difference in 
outcome between the two groups. However the study methods were poorly designed: 
no blinding was employed and the control group may have received suboptimal 
analgesia. Beattie et al have recently updated the results of their meta-analysis to 
include further randomised controlled trials. The use of thoracic epidural analgesia 
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continues to significantly reduce the rate of peri-operative MI with an OR of 0.6 and a 
p value of 0.03. 
 
Park et al (2001) conducted a randomised controlled trial comparing epidural 
anaesthesia and post-operative analgesia with general anaesthetic and systemic opioid 
analgesia. They included patients undergoing aortic, gastric, biliary and colonic 
procedures. There were multiple exclusions and a stratified randomisation technique 
was used. Some 18 (3.6%) of the 507 patients randomised to the epidural group 
suffered a myocardial infarction compared with 27 (5.3%) of 507 in the general 
anaesthesia group. The difference was not statistically significant (p=0.21). There 
were no cases of post-operative angina in the epidural group and 5 in the general 
group. This difference approached significance (p=0.07). When subgroups were 
analysed it became clear that differences between the two groups were most apparent 
in patients who had undergone aortic procedures. In the 184 such patients who had 
been randomised to the epidural group there were 5 events, compared with 15 events 
in the 190 general anaesthesia patients. The difference was statistically significant 
despite the fact that those patients who received epidural anaesthesia were more likely 
to have risk factors for ischaemic heart disease. The methodology for the study was 
clear and important pre- and intra- operative variables were taken into account. The 
stratified randomisation technique led to a good balance of prognostic factors between 
groups. However, no blinding was used in the study and no account was taken of 
beta-blocker or statin usage. In addition the study may have been underpowered due 
to the lower than expected event rate. The lack of significant effect of epidural 
anaesthesia in the reduction of events observed may therefore be secondary to a type 2 
error.  
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1.5 B-type Natriuretic Peptide (BNP) 
In 1981 de Bold and colleagues made the seminal observation that infusion of extracts 
of atrial tissue into rats caused a copious natriuresis (de Bold et al. 1981). This led to 
the subsequent isolation and cloning of atrial natriuretic peptide (ANP), a factor with 
potent natriuretic, diuretic and vasorelaxant properties. In 1988 a peptide with similar 
properties was identified in the porcine brain and therefore named brain natriuretic 
peptide (Sudoh et al. 1988). Although present in the human brain, highest 
concentrations are in fact found in the cardiac ventricles. Since then, C-type 
natriuretic peptide, a third compound with similar structure and pharmacological 
spectrum has also been discovered (Sudoh et al. 1990). Plasma levels of CNP are very 
low in humans. All 3 peptides share a common 17-amino acid ring structure and play 
an important physiological role in countering the effects of hypertension and plasma 
volume expansion with their natriuretic and vasodilatory actions. 
 
BNP is initially synthesised as preproBNP. This is first cleaved to proBNP and then to 
N-terminal-proBNP (NT-proBNP) and BNP in cardiac myocytes in response to atrial 
or ventricular stretch. Elevated levels of angiotensin 2 also stimulate secretion of 
BNP. The ventricle is the main site of BNP secretion (Mukoyama et al. 1991). 
 
Three natriuretic receptors have been identified in humans. Type A and type B are 
guanylate cyclase receptors and both are present in the lung, kidneys and adrenal 
glands. The A receptor has a greater affinity for ANP than BNP and is most abundant 
in large blood vessels. The B receptor primarily binds CNP and is predominately 
found in the brain (Nakao et al. 1992). The C receptor is mainly involved in the 
clearance of peptides.  
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In the cardiovascular system the natriuretic peptides reduce sympathetic tone in the 
peripheral vasculature causing fluid shifts by increasing the permeability of the 
vascular endothelium and increase venous capacitance. These actions lead to a 
decrease in pre-load and blood pressure. In the kidney the glomerular filtration rate 
(GFR) is increased through a combination of dilation of the afferent renal arterioles, 
constriction of the efferent renal arterioles, and relaxation of the tubular mesangial 
cells. The peptides have a direct natriuretic effect in the renal tubules, but also cause a 
reduction in plasma renin and aldosterone concentrations (Hunt et al. 1996).  In the 
brain stem, the natriuretic peptides serve to decrease sympathetic tone (Steele et al. 
1991) and inhibit vasopressin secretion. Centrally there is suppression of thirst and 
salt appetite (Burrell et al. 1991). 
 
BNP has a plasma half-life of 22 minutes (McCullough & Sandberg 2003), and its 
plasma concentration has been shown to have a direct relationship with changes in 
pulmonary artery wedge pressure over 2 hours (Kazanegra et al. 2001). Its 
concentration increases with age and is higher in women than in men. BNP is less 
affected by age and renal function than its precursor pro-BNP which can also be 
measured in plasma (McDonagh et al. 2004). 
 
Plasma BNP is most commonly assayed using immunoradiometric techniques 
however different assays will have different normal ranges of BNP meaning that 
absolute BNP concentrations between studies should not be directly compared unless 
the same assay has been used. 
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Plasma BNP concentration is a sensitive and specific predictor of left –ventricular 
systolic dysfunction (LVD) and has been shown to have an important diagnostic role 
in patients with heart failure. McDonagh et al (1998) randomly selected 2000 people 
from the North Glasgow population using a 2-stage process. The group were sent a 
questionnaire and the respondents were invited to attend for blood sampling, 
electrocardiography and echocardiography. Some 1252 participants had analysable 
electrocardiograms, echocardiograms and available blood samples and 37 of these 
were found to have left-ventricular systolic dysfunction (ejection fraction<30%). The 
BNP concentration was significantly higher in those patients with left-ventricular 
systolic dysfunction than in those with normal function (24 vs. 7.7 pg/ml). In patients 
over 55, a BNP concentration of >17.9pg/ml predicted heart failure with a sensitivity 
of 92% and a specificity of 72%. In multivariate analysis an increase in BNP 
concentration of 50% was a strong independent predictor of LVD. BNP was a more 
accurate predictor of LVD than NT-ANP and displaced it in the multivariate model.  
 
Cowie et al reported similar findings in their study of 122 patients referred to a rapid-
access heart-failure clinic (Cowie et al. 1997). Using clinical, radiological and 
echocardiographic parameters, 35 patients were given a diagnosis of heart failure. 
BNP samples were available for 29 of these. The median BNP concentration was 
significantly higher in those patients with heart failure than those with another 
diagnosis (63.9 vs. 13.9 pmol/l). A BNP level of 22.2pmol/l had a sensitivity of 97% 
and a specificity of 84% for the prediction of heart failure. Addition of ANP or NT-
ANP levels to a logistic regression model containing BNP concentration alone did not 
give any added value. 
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Renal function has also been shown to be an important determinant of BNP 
concentration with levels being inversely related to GFR (Mark et al. 2006;Vickery et 
al. 2005). GFR has been shown to be an independent determinant of plasma BNP and 
NT-pro BNP levels in patients with kidney disease (Vickery et al. 2005) and in fact 
one study has demonstrated that in patients with chronic kidney disease, GFR is a 
more important determinant of BNP than ventricular function (Mark et al. 2006). 
 
BNP has been shown to be an important prognostic indicator. Using the cohort of 
patients that had been recruited to assess the role of natriuretic peptides in the 
prediction of LVD (McDonagh et al. 1998) the same authors assessed the long-term 
prognostic role of BNP concentration (McDonagh et al. 2001). Patients were followed 
up for 4 years and all-cause mortality was 4.9%. The median BNP concentration in 
those patients who died was significantly higher than in survivors (16.9 vs 7.8 pg/ml) 
and a BNP level of greater than 17.9pg/ml was an independent predictor of mortality 
in sub-group analysis. Interestingly those patients with preserved left ventricular 
function and an elevated BNP concentration still had a poor prognosis. 
 
In another study analysing the prognosis of natriuretic peptides, Wang et al (2004a) 
studied a cohort of patients from the Framingham offspring study, excluding patients 
with a history of heart failure or biochemical renal impairment. BNP and NT-pro BNP 
concentration were measured in 3346 patients who were regularly monitored for the 
occurrence of cardiovascular outcomes or death. Follow-up was prospective and 
investigators were blinded to plasma natriuretic peptide levels. Median follow-up was 
5.2 years. In multivariate analysis, increasing plasma natriuretic peptide levels were 
significantly associated with an elevated risk of death, stroke, first cardiovascular 
 72 
event, atrial fibrillation and heart failure, the association being strongest with the last 
two. BNP tended to outperform NT-pro BNP in the prediction of events. There was 
however no association between natriuretic peptide levels and coronary heart disease 
events (MI, unstable angina).  
 
1.6 BNP as a predictor of perioperative cardiac morbidity  
When the present thesis was initiated, no researchers had as yet analysed the 
predictive value of BNP for peri-operative cardiac morbidity in non-cardiac surgery. 
However given the association identified in the literature regarding BNP 
concentration and cardiac outcome it was felt by the collaborating team that its 
measurement might be of use in peri-operative risk stratification. Furthermore, as 
serum BNP concentration is an accurate predictor of LVD (McDonagh et al. 1998) 
and the presence of heart failure has consistently been associated with increased peri-
operative risk it was logical that BNP levels could correlate with post-operative 
outcome. In Goldman’s cardiac index, clinical signs of heart failure were the most 
significant predictor of  fatal cardiac complications (Goldman et al. 1977) and in 
Lee’s RCRI a history of heart failure was a significant predictor of cardiac morbidity 
in both derivation and validation cohorts (Lee et al. 1999). In a meta-analysis by Shaw 
et al (1996) a history of heart failure was the second most significant predictor of poor 
cardiac outcome after the presence of a reversible perfusion defect on DTS.  
 
However BNP is not merely reflective of LVD. It has been described as a marker of 
cardio-renal distress and in those patients with a raised BNP and no evidence of LVD, 
some structural or functional cardiac or renal abnormality has often been found 
(McDonagh et al. 2004). This may enhance its use as a predictor of operative 
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morbidity. In fact, in a small pilot study BNP has also been shown to be a predictor of 
ischaemia during DSE (Asada et al. 2004). 
 
One prospective study has investigated the role of pre-operative BNP measurement in 
the prediction of peri-operative complications in cardiac surgery (Hutfless et al. 
2004). Of 98 male patients undergoing open heart surgery, 32 suffered a post-
operative cardiac complication, the majority of these being new arrhythmias. 
Although pre-operative BNP concentration was not associated with increased post-
operative cardiac events or 30 day mortality, it was significantly higher in patients 
who subsequently required the use of an intra-aortic balloon pump, and was 
associated with length of hospital stay and one-year mortality. A pre-operative 
concentration of 385pg/ml was the best predictor of these events. Although this level 
showed excellent accuracy (79%-86%) and specificity (90%) it was not sensitive 
(32%-50%) and positive predictive values although not documented in the published 
paper were low. Weaknesses of the study included lack of blinding, inadequate 
information on the influence of other risk factors, and insufficient sample size to 
allow detection of differences in BNP levels for some of the end-points. 
 
In 2005 Yeh et al (2005) analysed the utility of plasma NT-pro BNP levels in the 
prediction of cardiac complications after non-cardiac surgery. 190 patients were 
retrospectively studied and pre-operative NT-pro BNP levels were significantly 
higher in those patients who had a complication compared with those who did not 
(1215 vs.95 ng/l). Pre-operative NT-pro BNP concentration was the only independent 
predictor of outcome after multivariate analysis and a level of greater than 450ng/l 
had a 100% sensitivity and an 82.9% specificity of for the prediction of cardiac 
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events. It should be noted that the study was flawed, in that the population studied 
was heterogeneous (32 patients underwent minor surgery, and the remainder a major 
procedure), screening was not conducted for cardiac events, and no firm statistical 
guidance was involved in the study design. Furthermore, the selected end points were 
mostly subjective with limited clinical relevance. Only 4 patients fulfilled the 
objective end points of MI or cardiac death, the remainder suffering heart failure post-
operatively, the definition of which was open to interpretation. In the logistic 
regression model ASA grade was used despite the fact that other clinical models have 
been shown to be more accurate in the prediction of cardiac events. No information 
was available on intra-operative details nor of medications prescribed to patients and 
this may have influenced outcome.   
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1.6 Aims of this thesis 
Currently, no method of pre-operative cardiac risk prediction is sufficiently effective 
or practical to be of routine use. 
In this thesis the author has therefore set out the following objectives: 
 
1. To recruit a single hospital pilot cohort of consecutive patients undergoing major 
vascular surgery over a six-month time-period and determine whether pre-operative 
plasma B-type natriuretic peptide (BNP) concentration is associated with the 
occurrence of peri-operative myocardial infarction and cardiac death in this 
population. (Chapter 3) 
 
2. To study cardiac event rates and BNP levels in the pilot study and calculate the 
population size required for a validation cohort to allow determination of a BNP level 
at which cardiac risk increased.  To then recruit a cohort of consecutive patients 
undergoing major non-cardiac surgery (vascular surgery, laparotomy, and 
thoracotomy) in a single centre in order to determine whether pre-operative serum 
BNP concentration predicts the occurrence of peri-operative myocardial infarction 
and cardiac death in this wider setting. (Chapter 4) 
 
3. To determine whether cardiac troponin I levels are commonly raised prior to major 
vascular surgery and if so whether they are associated with the occurrence of peri-
operative myocardial infarction and cardiac death. (Chapter 5) 
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4. To determine whether pre-operative serum C-reactive protein levels are associated 
with the occurrence of peri-operative myocardial infarction and cardiac death in 
patients undergoing major vascular surgery. (Chapter 6) 
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2. Patients and Methods  
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2.1 Recruitment 
All patients undergoing major non-cardiac surgery in Gartnavel General Hospital and 
the Western Infirmary were prospectively identified using theatre diaries. Patients 
were included if they were over 40 years of age and undergoing major general, 
vascular or urological surgery which was expected to require a hospital-stay of more 
than 2 days. All patients were approached the day prior to surgery and informed 
consent was obtained (appendix 1). Patients were excluded if the surgery could not be 
delayed by more than 24 hours (due to clinical need), if they were unable to give 
informed consent or were being included in another study.  
 
2.2 Clinical details  
Patients’ clinical details were gathered prospectively and recorded on the study data-
sheet on the day prior to surgery (appendix 2). These included basic demographic data 
and factors relating to cardiac risk of surgery: age; sex; smoking history; medical 
diagnoses of angina, myocardial infarction, heart failure, hypertension, chronic 
obstructive airways disease cerebrovascular disease, hyperlipidaemia and medically 
treated diabetes. All patients’ current medications were noted.  
 
2.3 Pre-operative testing 
2.3.1 Pre-operative observations 
Pre-operative pulse and blood pressure were measured using a standard cardiac 
monitor. 
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2.3.2 Standard pre-operative investigations 
All patients underwent chest radiography and a twelve lead-electrocardiogram.  
2.3.3 Additional pre-operative investigations 
Additional pre-operative investigations were conducted at the discretion of surgical 
and anaesthetic staff. These included resting trans-thoracic echocardiography, 
pulmonary function tests and CT scanning. 
 
2.4 Venous blood sampling 
The patient lay supine for 20 minutes and a venous blood sample was taken for the 
following: 
2.4.1 Venous urea and electrolytes and plasma cholesterol 
A 5ml sample was taken in a lithium/heparin tube and sent to the biochemistry 
laboratory for measurement of venous urea and electrolytes, plasma total cholesterol, 
triglycerides and the HDL fraction of cholesterol. 
2.4.2 Full blood count and coagulation screen 
A 5 ml sample was taken in an EDTA tube for analysis of haemoglobin concentration, 
white cell count and platelet count. A further 5mls was taken in a citrate tube for 
analysis of pro-thrombin time, activated pro-thromboplastin time and fibrinogen.   
2.4.3 C-reactive protein (CRP) 
A 5ml sample was taken in a lithium/heparin tube and sent to the biochemistry 
laboratory for measurement of serum CRP. 
2.4.4 Cardiac troponin I (CTnI) 
A 5ml sample was taken in a lithium/heparin tube and sent to the biochemistry 
laboratory for measurement of cTnI. Sample results were not available to clinicians. 
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2.4.5 B-type natriuretic peptide (BNP) 
(a) Sample handling and plasma extraction 
A 10ml sample of blood was placed into a pre-chilled tube containing potassium-
EDTA (1mg/ml blood) and aprotonin (50 I.U./ml blood). The sample was stored on 
ice and centrifuged at 3000rpm for 10 minutes at 4°C immediately following 
collection. The plasma was then frozen and stored at -25°C until assay. 
(b) BNP assay 
BNP was assayed in unextracted plasma using a direct immunoradiometric assay kit 
(Shinoria BNP kit) supplied by Shinogi & Co, Ltd. (Osaka, Japan) (Kono et al 1993). 
This uses two monoclonal antibodies which recognise the carboxyl terminal sequence 
and the ring structure of human BNP, respectively, and measures it between the two 
antibodies without plasma extraction (Yasue et al 1994). The minimum detectable 
quantity of human BNP is 2pg/ml and the degree of cross reactivity with human ANP 
is less than 0.001% on a molar basis (Tsutamoto et al. 1997). The within-assay and 
between assay co-efficient of variation are both <5%. 
 
2.5 Clinical Scoring 
Using pre-operative information patients were attributed a clinical score using one 
and/or both of the following systems: 
(a) The Revised Cardiac Risk Index (RCRI) 
 This is an objective scoring system of cardiac risk based on the presence of six 
clinical variables (high-risk surgery, history of ischaemic heart disease, history of 
congestive heart failure, history of cerebrovascular disease, pre-operative treatment 
with insulin and pre-operative creatinine>2.0mg/dl). It categorises patients into four 
groups of increasing cardiac risk: 1. patients with 0 risk factors, 2. patients with 1 risk 
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factor, 3. patients with 2 risk factors, and 4. patients with 3+ risk factors. All patients 
were given an RCRI score. 
  
(b) The Eagle score 
This clinical scoring system is dependent on five variables: age over 70; diabetes; 
history of angina; ventricular ectopics requiring treatment; and Q-waves on ECG. The 
presence of none of the criteria puts a patient in a low risk category, 1or 2 in a 
moderate risk category and 3 or more in a high risk category. All patients undergoing 
vascular surgery were given an Eagle score. 
 
2.6 Intra-operative details 
Intra-operative details were prospectively documented and included: 
2.6.1 Anaesthetic technique 
The method of anaesthesia employed was recorded. 
2.6.2 Duration of procedure 
This was noted from anaesthetic charts. 
2.6.3 Intra-operative blood loss 
Intra-operative blood loss was estimated through measurement of losses in suction 
and the weighing of surgical swabs. 
 2.6.4 Intra-operative hypotension 
 This information was abstracted from anaesthetic charts. Intraoperative hypotension 
was defined as a systolic blood pressure below 90mmHg for a period of greater than 5 
minutes. 
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2.7 Post-operative testing 
All patients were screened for post-operative cardiac events. Other post-operative 
investigations were conducted at the discretion of the treating physicians.  
 
2.7.1 Twelve lead electrocardiography (ECG) 
This was conducted routinely on the mornings of the second and fifth post-operative 
days, the morning of discharge and at out-patient clinic six weeks following surgery. 
It was also conducted at other times as clinically indicated at the discretion of the 
treating physicians. 
 
2.7.2 Cardiac troponin I sampling  
Venous blood sampling for cardiac troponin I analysis was conducted routinely on the 
mornings of the second and fifth post-operative days, prior to discharge and at out-
patient clinic six weeks following surgery. It was also conducted at other times as 
clinically indicated at the discretion of the treating physicians. 
 
2.8 Study end points  
The study end points were non-fatal myocardial infarction (MI), and cardiac death. 
2.8.1 Timing 
Patients were followed up for six weeks and any events occurring up to 6 weeks 
following surgery were included and analysed.  
2.8.2 Non-fatal myocardial infarction 
The definition of MI was that used by The Joint European Society of 
Cardiology/American College of Cardiology Committee, defined as “a typical rise 
and gradual fall of cTnI with at least one of the following: a) ischaemic symptoms; b) 
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development of pathological Q waves on the ECG; c) ECG changes indicative of 
ischaemia (ST segment elevation or depression); or d) coronary artery intervention.” 
 
2.8.3 Cardiac death 
Cardiac death was defined as death secondary to myocardial infarction, cardiogenic 
shock or intractable dysrhythmias.  
2.8.4 Interpretation of cardiac events 
The decision of whether end points had been fulfilled was determined by a review of 
all post-operative data by 2 cardiologists who were blinded to pre-operative BNP 
levels. 
 
2.9 Cardiac troponin I analysis 
Serum cTnI was measured using the ADVIA Centaur® immunoassay (Bayer 
Diagnostics), which has a sensitivity and assay range of 0.1-50ng/ml. 
 
2.10 Twelve lead electrocardiogram (ECG) 
2.10.1 Recording 
This was recorded in a standard fashion at a paper speed of 25mm/second by a 
qualified cardiac technician. 
2.10.2 Analysis  
All ECGs were interpreted by two experienced cardiologists blinded to patient and 
clinical details. They commented on the presence of an abnormal ECG preoperatively, 
and of electrocardiographic evidence of an MI. If there was any disagreement a third 
cardiologist was asked to make a determination. 
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2.11 Definitions 
2.11.1 Ischaemic heart disease 
Ischaemic heart disease was defined as the presence of one or more of: 1. history of 
myocardial infarction; 2. history of positive exercise test; 3. current complaint of chest 
pain considered to be secondary to myocardial ischaemia; 4. regular nitrate therapy; 5. 
ECG with pathological Q waves. 
2.11.2 Heart Failure 
Heart failure was defined as one or more of the following: 1.previous medical 
diagnosis of heart failure; 2. pulmonary oedema; 3. paroxysmal nocturnal dyspnoea; 
4. physical examination showing bilateral rales or S3 gallop; 5. chest radiograph 
showing pulmonary vascular redistribution; 6. echocardiography showing reduced left 
ventricular ejection fraction (<40%).  
2.11.3 Diabetes Mellitus 
This was defined as the presence of a medical diagnosis of diabetes mellitus with the 
current use of insulin or oral hypoglycaemic agents. 
2.11.4 Cerebrovascular Disease 
Cerebrovascular disease was defined as previous medical diagnosis of 
cerebrovascular accident or transient ischaemic attack. 
2.11.5 Hyperlipidaemia  
Hyperlipidaemia was defined as a pre-operative cholesterol of >5.5mmol/l 
2.11.6 Renal Impairment 
Renal impairment was defined as a pre-operative creatinine of >130mmol/l. 
2.11.7 Procedures 
Patients undergoing emergency surgery (<24 hours from admission) were excluded. 
Procedures were classed urgent if they were conducted on the same admission as a 
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referral from the emergency department or another source, but did not require to be 
conducted within 24 hours. Procedures were considered elective if patients were 
admitted from home for treatment. The following procedures were included 
appropriate to each study’s entry criteria. 
(a) Aortic aneurysm repair 
This was performed with either aortic tube or aortic bifurcation grafting as 
appropriate. No endovascular procedures were included in this study. 
(b) Aorto-bifemoral bypass grafting 
An onlay aortic graft was performed to appropriate infra-inguinal target vessels. 
(c) Non-aortic vascular reconstruction 
This included femoro-popliteal grafting, femoro-distal grafting, femoral 
endarterectomy, axillo-bifemoral grafting, and carotid-subclavian bypass surgery. 
(d) Major lower extremity amputation 
This included above-knee and below-knee amputation for critical limb ischaemia but 
excluded more distal procedures. 
(e) Intra-abdominal non-vascular surgery (laparotomy) 
This included total and sub-total gastrectomy for malignancy, Whipple’s procedure 
for pancreatic/bilary malignancy and colorectal resection for malignant or 
inflammatory bowel disease. Laparoscopic procedures were not included. 
(f) Nephrectomy 
Total or partial nephrectomy for malignancy was included. 
(g) Oesophago-gastrectomy 
This was performed for oesophageal malignancy using the Ivor-Lewis technique, 
involving both intra-abdominal and intra-thoracic approaches. 
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2.12 Statistical analysis 
Statistical analysis was conducted using SPSS® statistical software package (SPSS, 
Chicago, Illinois, USA). Univariate analyses between groups were conducted using 
Pearson’s chi-squared test or a two tailed Fisher’s exact test. Statistical analysis of 
continuous data was performed using a Mann-Whitney test. ROC curves were created 
to determine the association between BNP/CRP and cardiac outcome. A logistic 
regression model was fitted with cardiac events as outcome and the natural logarithm 
of BNP (logeBNP) as covariate. A probability value of less than 0.05 was considered 
statistically significant. 
 
2.12 Ethics 
The study was approved by West Glasgow Ethics Committee. All patients gave their 
written consent to the study on admission to hospital. 
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3. A Pilot Study to Evaluate the Value of B-type 
Natriuretic Peptide (BNP) In Predicting Cardiac 
Morbidity after Vascular Surgery 
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3.1 Introduction 
Vascular surgery is associated with substantial risk of cardiovascular events and death 
(Kim et al. 2002). Currently, there is no effective method of determining cardiac risk 
pre-operatively: validated risk prediction instruments are limited by their complexity 
and poor predictive value (Detsky et al.  1986;Lee et al. 1999b), whilst other cardiac 
investigations such as nuclear stress testing and coronary angiography are limited by 
time and resources. For these reasons, alternative methods that could predict outcome 
in at-risk patients would represent an important advance. 
 
Plasma BNP has counter-regulatory vasodilator and natriuretic properties (Hunt et al. 
1996) and its concentrations are increased and relate to prognosis in cardiac disorders, 
such as angina and heart failure (McDonagh et al. 1998;Wang et al. 2004b). Many of 
these cardiovascular disorders occur in patients with peripheral vascular disease. 
 
The aim of this study was to investigate the predictive value of pre-operative plasma 
BNP concentration for the occurrence of peri-operative fatal or non-fatal myocardial 
infarction (MI) in a high-risk cohort of vascular surgical patients. Results from this 
study would then be used to help calculate a sample size for a study examining a more 
general population.  
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3.2 Patients and Methods 
3.2.1 Study population 
Consecutive patients undergoing major surgery for aortic or peripheral arterial 
occlusive disease in Gartnavel General Hospital were screened between April and 
September 2004. A sample size (n=40) had been calculated based on i) an anticipated 
rate of fatal or non-fatal MI of 10%, and ii) median (interquartile range) BNP 
concentrations in patients with or without cardiovascular disease who had participated 
in the North Glasgow MONICA study. 
 
3.2.2 Preoperative testing 
All patients underwent conventional pre-operative preparation, which included 
routine blood tests, an ECG and a chest radiograph. Additional tests, such as 
echocardiography, were performed at the discretion of the surgical team. BNP 
samples were collected and analysed using the techniques described in section 2.4.5. 
Batch analysis of the BNP samples was performed at the conclusion of the study by a 
biochemist blinded to clinical detail. In addition, to detect if any patient had 
asymptomatic cardiac disease, cardiac troponin I (cTnI) was measured pre-operatively 
(ADVIA Centaur assay, Bayer Diagnostics). The result of this was not available to 
clinicians. 
 
3.2.3 Study end-points 
The study end points that were used were non-fatal myocardial infarction, and cardiac 
death. The definition of myocardial infarction was that of The Joint European Society 
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of Cardiology/American College of Cardiology Committee as described in section 
2.8.2 (Alpert et al. 2000). Cardiac death was defined as death secondary to myocardial 
infarction, cardiogenic shock or intractable dysrhythmia and was determined by a 
review of all post-operative data by 2 cardiologists blinded to pre-operative BNP 
levels. Patients were followed up for six weeks after surgery. 
 
3.2.4 Post-operative screening for cardiac events 
Post-operative screening for cardiac events consisted of daily clinical assessment, 
serial ECGs and cTnI measurement (post-operative days 2 and 5, prior to discharge 
and at out-patient follow-up around day 42). Other investigations were conducted as 
clinically indicated. ECG analysis was performed by 2 cardiologists blinded to all 
other data and patient details, in a batch at the end of the study period. Ten percent of 
all ECGs, clinical notes and data entry was analysed separately to ensure quality 
control.  
 
3.2.5 Statistical analysis 
Statistical analysis of continuous data was performed using a Mann-Whitney test. 
Categorical data was analysed using a Pearson’s chi-squared test or a two-tailed 
Fishers’ exact test. Values are reported as median (interquartile range). As a BNP 
concentration of 100pg/ml had previously been shown to be predictive of heart failure 
this value was initially used to compare BNP with other factors. 
 
Local research and development, and ethics approval was obtained and a statistician 
consulted for study design and data analysis. 
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3.4 Results 
Forty-one patients were included (Table 3.1). Of these, 17 underwent lower limb 
bypass surgery, 11 had aortic surgery, and 13 underwent major lower limb 
amputation. Post-operatively, 4 patients died from an acute MI and 7 other patients 
experienced a non-fatal MI, 3 of which were clinically silent. Events were most 
common in the first 48 hours (7), but did occur from 48 hours to 1 week (3), and up to 
6 weeks post-operatively (1).   
 
Patients with pre-existing cardiac disease, renal impairment or who suffered intra-
operative hypotension were more likely have a cardiac event. Patients prescribed beta 
blockers had a lower cardiac event rate. The Eagle score but not the RCRI was a 
significant predictor of cardiac outcome (Table 3.1). 
 
BNP concentration correlated with operative risk factors with higher levels in patients 
with cardiac disease, diabetes mellitus and renal impairment (Table 3.1). 
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Table 3.1: The case mix and cardiac event rate 
 
                      Cardiac Event Rate          
Case Mix    BNP* (pg/ml)   n†    %  p 
 
Sex      Male 60 (16-148)  7/25  28.0   
Female 58 (32-132)  4/16  25.0        1.000
     
IHD                  Absent 37 (12-111)  5/23  21.7  
          Present 88 (32-203)  6/18  33.0        0.489
   
Heart failure        Absent        43 (15-111)           6/31        19.3  
                            Present       138 (25-203)          5/10        50.0        0.098 
 
β-blockers     Used  36 (15-121)  1/7          14.3 
                            Not Used     65 (20-146)                10/34  29.4            0.651                                 
 
Diabetes      Absent 37 (16-118)  7/29  24.1 
                            Present       101 (48-240)  4/12  33.0        0.701
  
Renal                   Absent        52 (20-123)            9/37        24.3    
impairment          Present       225 (19-532)           2/4          50.0            0.288 
 
COPD                  Absent 70 (19-146)          10/34  29.4  
                     Present 27 (13-93)  1/7  14.3        0.651 
 
Intraoperative      Absent 42 (16-119)            8/36        22.2   
hypotension         Present      139 (85-206)           3/5          60.0            0.110 
 
Eagle   0 16 (10-30)  0/12    0.0 
   1 69 (18-174)  6/14  42.9 
   2 88 (67-169)  2/10  20.0 
   3        172 (96-321)  3/5  60.0        0.026‡ 
  
RCRI   0  71 (17-124)  3/11  27.3     
                                    1    36 (13-57)                   3/17  17.6 
    2 81 (50-236)  1/6  16.7 
   3+ 172 (85-210)  4/7  57.1            0.229‡ 
 
BNP*= Median pre-operative BNP concentration (interquartile range)  
†The numerator indicates the number of subjects who experienced a cardiac event and the denominator 
indicates the total number of subjects who share an attribute ie 7 out of 27 men experienced a cardiac 
event. p values derived from two-tailed Fishers’ exact test.   
‡ p value derived from χ2 
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The median (interquartile range) plasma BNP concentration in patients who 
experienced a fatal or non-fatal MI (n=11) was 210 (165-380) pg/ml, compared to 
34.5 (14-70) pg/ml in those who did not (n=30), p<0.001 (Figure 3.1). All patients 
who experienced an event had a preoperative BNP concentration greater than >123 
pg/ml. All patients who were event free had a BNP of <122pg/ml.  
 
 
Figure 3.1 BNP and cardiac events 
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3.4 Discussion 
This study has shown that pre-operative plasma BNP concentrations are elevated in 
patients who subsequently experience a peri-operative fatal or non-fatal MI. In fact 
there was no cross-over in BNP concentrations between those patients who did and 
those who did not suffer a cardiac event; a BNP level of 123pg/ml being completely 
discriminatory. 
 
In this study no single clinical variable (other than BNP concentration) was 
significantly predictive of outcome, although patients with pre-existing cardiac or 
renal disease were more likely to suffer a cardiac event. Patients’ whose operation 
involved a period of hypotension had a higher cardiac event rate and if beta blockers 
were prescribed the likelihood of a cardiac event was halved, in keeping with the 
cardio-protective role of these drugs. The Eagle clinical scoring system (Eagle et al. 
1989) was a significant predictor of outcome, however the RCRI (Lee et al. 1999b) 
was not, in keeping with the fact that the former but not the latter was derived in a 
cohort of vascular patients. 
 
In the recent Coronary Artery Revascularization Prophylaxis trial, 510 patients with 
obstructive coronary artery disease and an indication for vascular surgery were 
randomised to coronary revascularisation before surgery or to conventional 
management (McFalls et al. 2004). Perhaps surprisingly, coronary revascularisation 
did not confer any survival advantage. This result illustrates the complexity of risk 
management in high-risk surgical patients and underscores the need for further 
investigations in this area. 
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Results from this study suggest that a single pre-operative blood BNP measurement 
may predict risk in this, and potentially other, surgical settings. BNP concentration 
measured prior to surgery may lead to a change in the management plan. This thesis 
requires validation in a larger population of patients. If reproduced, these findings 
could enhance the cost-effectiveness of interventions in patients with surgical disease. 
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4. B-type Natriuretic Peptide (BNP) Predicts Cardiac 
Morbidity and Mortality after Major Surgery:  
A Prospective Study 
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4.1 Introduction 
Cardiovascular disease is the leading cause of mortality in surgical patients (Mangano 
1990). Despite this, current methods of peri-operative cardiac risk stratification 
remain flawed: clinical scoring systems, although simple to use, are limited by their 
predictive value (Lee et al. 1999b), whilst other cardiac investigations such as nuclear 
stress testing are highly sensitive (Poldermans et al. 1993), but limited in practice by 
time and resource implications. A simple, practical and accurate method of predicting 
cardiac morbidity would therefore be of great benefit.   
 
B-type natriuretic peptide (BNP) was originally identified in the porcine brain (Sudoh 
et al. 1988), although its main site of secretion is from atrial, and in particular 
ventricular myocytes in response to cardiac wall stress (Mukoyama et al. 1991). It has 
potent natriuretic, diuretic and vasorelaxant properties, and inhibits the release of 
aldosterone via the renin-angiotensin system (Hunt et al. 1988). Recent studies have 
demonstrated that the concentration of BNP in plasma has many clinical applications: 
it is a sensitive and specific predictor of left–ventricular systolic dysfunction 
(McDonagh et al.  1998), and  predicts first cardiovascular event and mortality in the 
general population (McDonagh et al. 2004a). 
 
Few studies have evaluated pre-operative BNP concentration as a method of 
predicting cardiac complications in surgical patients. The only prospective study to do 
so correlated pre-operative BNP concentration with outcome following cardiac 
surgery (Hutfless et al. 2004). No study has evaluated BNP concentration as a 
predictor of cardiac risk in non-cardiac surgical patients, although one recent 
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retrospective study did predict the occurrence of cardiac failure following non-cardiac 
surgery using the BNP precursor, plasma N-terminal pro-BNP (Yeh et al. 2005). 
 
The previous section of this thesis found pre-operative BNP concentration to be a 
significant predictor of cardiac outcome following vascular surgery with a value of 
123pg/ml being completely discriminatory for the occurrence of cardiac events. The 
aim of this study was to validate the proposal that pre-operative BNP concentration 
predicted post-operative cardiac outcome, but this time in a larger heterogeneous 
group of patients undergoing major non-cardiac surgery. 
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4.2 Patients and Methods 
4.2.1 Study Design 
A prospective, observational, single centre cohort study was conducted on the basis of 
the findings of the pilot study (chapter 3). Using the BNP concentrations in the group 
of high-risk patients who underwent major vascular surgery, and an expected cardiac 
event rate of 5% in the patients undergoing non-vascular surgery a sample-size 
(n=140) was determined. The initial cohort of patients (chapter 3) had been chosen to 
ensure that the numbers of patients at risk of cardiac events was sufficient to show a 
significant difference should one exist; this second cohort was chosen to determine 
the widespread applicability of the initial findings to the general surgical population, a 
group in which a lower cardiac event rate is to be anticipated. The methods used in 
this validation study were consistent with those employed in the pilot study (see 
chapter 3). 
 
4.2.2 Patients 
Patients undergoing non-cardiac surgery with an estimated cardiac complication rate 
of greater than 5% (vascular surgery, laparotomy, and thoracotomy) were 
prospectively recruited over a period of one year. Patients were excluded if surgery 
was emergency (surgery being required within 24 hours), or if informed consent was 
not obtainable. 
 
Basic demographic data and factors relating to the cardiac risk of surgery were 
prospectively gathered for each patient. These included: clinical variables (history of 
cardiovascular, renovascular, cerebrovascular and pulmonary disease), medications 
prescribed, and intra-operative details (length of operation, intra-operative 
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hypotension, operative blood loss). Ischaemic heart disease (IHD) and heart failure 
were classified using established definitions (Lee et al. 1999b). Renal impairment was 
defined as a pre-operative creatinine of greater than 130µmol/l and intra-operative 
hypotension as a systolic blood pressure of less than 90mmHg for more than 5 
minutes during surgery.  
 
The risk of cardiac events was objectively calculated using  the revised cardiac risk 
index (RCRI), (Lee et al. 1999b) with the cumulative scoring system allowing 
categorisation of patients into 4 groups of increasing cardiac risk. 
 
4.2.3 Preoperative assessment 
 
Pre-operative assessment and investigation were at the discretion of the surgical and 
anaesthetic teams and included routine blood tests, an ECG and a chest radiograph. 
BNP samples were collected and analysed using the techniques described in section 
2.4.5. Batch analysis of the BNP samples was performed at the conclusion of the 
study by a biochemist blinded to clinical detail. In addition, to detect if any patient 
had asymptomatic cardiac disease, cardiac troponin I (cTnI) was measured pre-
operatively (ADVIA Centaur assay, Bayer Diagnostics). These results were not 
available to clinicians.  
 
 
4.2.4 Study end-points 
 
The study end points were non-fatal myocardial infarction (MI), and cardiac death. 
The definition of myocardial infarction was that of The Joint European Society of 
Cardiology/American College of Cardiology Committee (Alpert et al. 2000). Cardiac 
death was defined as death secondary to myocardial infarction, cardiogenic shock or 
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intractable dysrhythmia, and was determined by a review of post-operative data by 2 
cardiologists who were blinded to pre-operative BNP levels. Patients were followed 
up for six weeks after surgery. 
 
4.2.5 Post-operative screening 
Post-operative screening for cardiac events consisted of daily clinical assessment, 
serial ECGs and cTnI measurement (post-operative days 2, 5, prior to discharge and 
day 42). Other investigations were conducted as clinically indicated. ECG analysis 
was performed by 2 cardiologists blinded to all other data and patient details, in a 
batch at the end of the study period. In a random sample of 10% of patients, ECGs, 
clinical notes and data entry were analysed separately in order to ensure quality 
control.  
 
4.2.6 Statistical analysis 
Statistical analysis was conducted using SPSS® statistical software package (SPSS, 
Chicago, Illinois, USA). BNP values are reported as median (interquartile range). 
Univariate analyses between groups were conducted using Pearson’s chi-squared test 
or a two-tailed Fisher’s exact test. Continuous variables were compared using a 
Mann-Whitney test. A logistic regression model was fitted with cardiac events as 
outcome and the natural logarithm of BNP (logeBNP) as covariate. The odds ratio 
(OR) for a one unit change in logeBNP and its 95% confidence interval (CI) were 
calculated. 
 
Local research and development and ethical approval were obtained and a medical 
statistician consulted for study design and data analysis. 
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4.3 Results 
4.3.1 Study Population 
One hundred and forty-nine patients were prospectively recruited over a one-year 
period. As in the pilot study, the median age was 68 years (60-76). Other than this, the 
two cohorts were not similar (Table 4.1). Ischaemic heart disease (21% vs. 44%) and 
heart failure (17% vs. 24%) were less prevalent and while all patients in the derivation 
cohort had undergone major vascular surgery, the validation cohort was composed of 
patients undergoing major non-cardiac surgery (laparotomy-49, peripheral bypass-39, 
amputation-25, aortic procedure-24, nephrectomy-7, oesophago-gastrectomy-5). The 
cardiac event rate was lower in this cohort (10% vs. 27%), as was the percentage of 
patients with a BNP of greater than 100 pg/ml (23% vs. 34%). As previously noted, 
BNP concentrations correlated with cardiac risk factors, higher levels being observed 
in patients with heart failure, ischaemic heart disease, diabetes mellitus and renal 
impairment (Tables 4.2). 
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Table 4.1 The case mix of derivation and validation cohorts. 
                    
Case Mix         Cohort:        Derivation          Validation                p   
                                                                            n (%)                  n  (%) 
 
 
Male Sex     25 (61) 99 (66)            0.579 
  
Ischaemic Heart Disease   18 (44) 32 (21)            0.008 
   
Heart Failure                        10 (24)     25 (17)            0.264 
                                     
β-blocker prescribed     7 (17)  30 (20)            0.824 
 
Diabetes Mellitus                 12 (29)  30 (20)   0.211           
   
Renal Impairment                                 4 (10)   21 (14)            0.606 
 
Cerebrovascular disease                       1   (2)   17 (11)            0.129 
 
Chronic Obstructive Lung Disease       7 (17)  25 (17)            1.000 
 
 Intraoperative  hypotension                  5 (12)   30 (20)            0.362 
 
Revised cardiac index   0  11 (27) 26 (17)            0.267  
 1     17 (41) 85 (57)            0.081 
 2       6 (15) 21 (15)            1.000 
     >2      7 (17) 17 (11)            0.424 
 
BNP 100+                   14 (34) 35 (23)            0.226 
   
 
Cardiac events                                11 (27) 15 (10)            0.010 
 
 
Total    41 (100)         149 (100) 
 
 
 
 
 
p values derived from two-tailed  Fishers’ exact test. 
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4.3.2 Cardiac Events 
A total of 149 patients (99 males, 50 females) were recruited to the validation study 
and underwent major non-cardiac surgery (Table 4.1). There were 15 cardiac events: 
8 non-fatal myocardial infarctions (amputation-3, laparotomy-2, aortic surgery-2, 
peripheral bypass surgery-1); and 7 cardiac deaths (amputation-3, laparotomy-2, 
aortic surgery-1, peripheral bypass surgery-1). Three of the non-fatal myocardial 
infarctions were silent and detected by post-operative screening at 48 hours. As in the 
pilot study, events were most common in the first 48 hours (9), but did occur from 48 
hours to 1 week (3), and up to 6 weeks post-operatively (3).   
 
Cardiac events were more common in patients with ischaemic heart disease (15.6% 
vs. 8.5%), cerebrovascular disease (17.6% vs.9.1%), or pre-operative renal 
impairment (19% vs. 8.6%), (Table 4.2). Patients who underwent a vascular 
procedure (12.5% vs. 6.6%) or whose procedure involved a period of hypotension 
(16.7% vs. 8.4%) were also more likely to have a cardiac event.  Although the RCRI 
was not discriminatory between the event rates in the lowest two risk categories, 
patients in the three highest risk categories had an increasing likelihood of suffering a 
cardiac event (8.2%, 9.5% and 17.6%). When only the 61 non-vascular patients were 
considered, the RCRI was again inconsistent in its predictive ability: 3 of the 51 
patients (5.9%) with an RCRI of 1 had an event; and 1 of 6 patients (16.7%) with an 
RCRI of 2 had an event however none of the 4 patients with an RCRI of 3 suffered a 
cardiac event. 
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Table 4.2 Validation cohort: the case mix and cardiac event rate. 
     Cardiac Event Rate          
Case Mix                BNP*       n†    %            p 
 
Sex      Male  33 (13-88)   10/99     10.1   
      Female  41 (11-104)   5/50     10.0  1.000 
 
Ischaemic heart   Absent  28 (10-80)   10/117   8.5 
disease      Present   83 (23-149)     5/32     15.6  0.316 
 
Heart failure     Absent            30 (11-81)         12/124   9.7                       
       Present     91 (38-351)         3/25    12.0      0.718
 
β-blockers     Used   82 (37-170)     7/30     23.3 
      Not Used  30 (11-81)     8/119   6.7  0.014 
 
Statin      Used  39 (16-115)     9/62     14.5   
      Not Used            30 (11-85)     6/87       6.9  0.168  
 
Diabetes      Absent  32 (13-82)         11/119   9.2 
      Present  74 (12-146)         4/30     13.3      0.504 
 
Cerebrovascular  Absent  33 (12-90)         12/132    9.1                     
disease      Present   38 (17-164)         3/17           17.6      0.382 
 
COPD               Absent  36 (12-103)   13/124 10.5 
                           Present  32 (14-87)     2/25        8.0  1.000 
 
Renal               Absent   32 (11-85)        11/128   8.6 
impairment          Present  63 (23-362)         4/21   19.0      0.230 
 
Operation     Vascular   39 (15-102)        11/88   12.5                   
       Non-vascular  28 (10-78)                4/61       6.6     0.279 
 
Intra-operative    Absent   40 (12-95)        10/119   8.4                  
hypotension      Present  34 (13-93)          5/30     16.7      0.185                
 
Blood loss (mls)  <500  31 (10-93)    11/112   9.8   
       500+  40 (29-99)     4/37     10.8 1.000 
 
Operation length  <2   37 (13-110)     8/86       9.3  
        (hrs)      2+   34 (11-88)     7/63     11.1 0.786 
 
 
RCRI                      0    46 (15-90)          3/26  11.5 
                               1     28 (10-63)          7/85       8.2 
           2     69 (34-154)         2/21       9.5 
                     3+    91 (31-150)         3/17           17.6   0.691‡            
 
 
 
BNP* = Median BNP (interquartile range) 
†
 The number of subjects who experienced a cardiac event over the total number  
p values derived from two-tailed Fishers’ exact test, ‡ p value derived from χ2 
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4.3.4 BNP concentration and outcome 
The median (interquartile range) pre-operative BNP concentration was significantly 
higher in patients who had a cardiac event than in those who did not (351 (127-1034) 
vs. 30.5 pg/ml (11-79.5), p<0.001, Figure 4.1). For each increment in logeBNP the OR 
was 3.85, 95% CI (2.19- 6.78) (figure 4.2). The median (interquartile range) BNP 
level in patients who suffered a fatal event was higher than in those who suffered a 
non-fatal myocardial infarction (743 (184-1034) vs. 247.5 pg/ml (63-1046), p=0.463).  
 
 
Figure 4.1 BNP concentration and cardiac events 
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Figure 4.2 LogeBNP concentration and cardiac events 
 
 
A logistic regression model was fitted with cardiac events as outcome and the natural 
logarithm of BNP as covariate. The OR for a one unit change in logeBNP and its 95% 
CI was calculated. The logistic regression model demonstrated a highly significant 
association between logeBNP and the risk of a cardiac outcome (OR= 13.69, 95%CI 
(3.62-51.83), P<0.001). Adjustment for additional risk factors was explored (Table 
4.3). This had no effect on reducing the statistical significance of logeBNP as a 
predictor of events. However, there was evidence that the statistical model was 
becoming unstable, with the OR for logeBNP increasing dramatically (as did its 95% 
CI) and other terms having very large or very small ORs with wide confidence 
intervals. 
 
 
 
 108 
 
Table 4.3 Logistic Regression Table 
 
                                                  Odds      95% CI 
Predictor          Coef   SE Coef      Z      P  Ratio  Lower   Upper 
Constant       -9.13180   4.17241  -2.19  0.029 
logbnp          2.61678  0.679192   3.85  0.000  13.69   3.62   51.83 
SEX           -0.575739   1.00572  -0.57  0.567   0.56   0.08    4.04 
IHD2          -0.310073   1.08579  -0.29  0.775   0.73   0.09    6.16 
HF2            -4.91978   2.11415  -2.33  0.020   0.01   0.00    0.46 
CVA2           0.416425   1.28320   0.32  0.746   1.52   0.12   18.76 
RF2           -0.749416   1.17093  -0.64  0.522   0.47   0.05    4.69 
OpVasc       -0.0152394   1.12753  -0.01  0.989   0.98   0.11    8.98 
betab          0.709553  0.998672   0.71  0.477   2.03   0.29   14.40 
stat            1.27782   1.05039   1.22  0.224   3.59   0.46   28.12 
hypotension     2.90674   1.22955   2.36  0.018  18.30   1.64  203.70 
 
 
Log-Likelihood = -20.085 
Test that all slopes are zero: G = 57.144, DF = 10, P-Value = 0.000 
 
 
For all categories of the revised cardiac risk index, the median BNP level was higher 
in patients who had a cardiac event than those who did not (RCRI=0 (895 vs. 32 (13-
81) pg/ml) p=0.001, RCRI=1 (184 (127-351) vs. 25 (9-50) pg/ml) p<0.001, RCRI= 2 
(1060 vs. 46 (31-144) pg/ml) p=0.152, RCRI 3+ (1034 vs. 77 (31-169) pg/ml) p=0.24.  
 
The median BNP concentration was higher in patients who had a cardiac event 
whether patients underwent vascular surgery (850 (144-1111) vs. 37 (13-84) pg/ml, 
p<0.001) or non-vascular surgery (211 (115-337) vs. 26 (9-52) pg/ml, p=0.001). 
 
Receiver operating characteristic (ROC) curve analysis was performed to identify the 
BNP concentration that best predicted cardiac events (figure 4.3). The area under the 
ROC curve was 0.907. A BNP concentration of 108.5 pg/ml had the best combined 
sensitivity (87%) and specificity (87%). Some 31(20.8%) of patients had a pre-
operative BNP concentration of greater than this value which had a positive predictive 
value of 42% and a negative predictive value of 98%. To substantially increase the 
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positive predictive value it was necessary to increase the threshold BNP concentration 
to 180pg/ml. This level of BNP had a sensitivity of 67%, a specificity of 93%, a 
positive predictive value of 53% and a negative predictive value of 96%. 
 
Figure 4.3 ROC curve: BNP concentration and cardiac events 
 
 
A BNP concentration of 108.5pg/ml predicted outcome whether ischaemic heart 
disease was present or not, and in all classes of the RCRI, although this was only 
significant in the lowest 2 categories due to the fewer numbers analysed in the higher 
risk categories (Table 4.4). A BNP concentration of greater than 108.5pg/ml also 
remained predictive irrespective of the type of surgery. In fact, no cardiac events 
occurred in patients undergoing non-vascular surgery with a BNP of less than 
108.5pg/ml (Table 4.4). 
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Table 4.4 The cardiac event rate by risk factors and BNP levels in the validation 
cohort 
 
                      Cardiac Event Rate          
Risk Factor                                BNP (pg/ml)  n†    %  p 
 
 
Ischaemic Heart Absent  <108.5  1/97   1.0     
       Disease                      108.5+  9/20  45.0      0.000    
 
              Present <108.5  1/21   4.8  
                              108.5+  4/11  36.4      0.037
    
Revised Cardiac      0         <108.5  0/21         0.0  
         Index            108.5+  3/5      60.0      0.004 
 
 
          1         <108.5  1/73        1.4  
             108.5+  6/12      50.0      0.000                 
                                               
                                        2         <108.5  0/13             0.0   
                                                         108.5+   2/8              25.0      0.133 
 
 
                                         3+           <108.5       1/11              9.1                                                                                              
                                                          108.5+   2/6             33.3      0.515 
 
 
Operation    Non-vascular        <108.5  0/51      0.0   
              108.5+  4/10  40.0      0.000
  
   
                           Vascular         <108.5  2/67  3.0     
              108.5+  9/21      42.9      0.000 
                     
 
 
 
†The number of subjects who experienced a cardiac event over the total number  
 
p values derived from two-tailed Fishers’ exact test 
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ROC curve analysis was performed separately in the non-vascular and vascular cohorts. 
In the non-vascular cohort the area under the curve was 0.939, with a BNP of 108.5pg/ml 
having the best combined sensitivity (100%) and specificity (89%), (figure 4.4). In the 
vascular cohort the area under the curve was 0.884 with a level of 140.5pg/ml having the 
best combined sensitivity (82%) and specificity (86%), (figure 4.5).  
         
Figure 4.4 
ROC curve: BNP concentration and cardiac events in non-vascular patients 
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Figure 4.5  
ROC curve: BNP concentration and cardiac events in vascular patients 
 
 
 
4.3.5 Application of best performing BNP concentration to the pilot cohort 
These best performing BNP concentrations were then applied to the cohort of patients 
studied in chapter 3. In this group a BNP of 108.5 pg/ml had a sensitivity of 100% and a 
specificity of 90% and a BNP of 140.5pg/ml had a sensitivity of 82% and a specificity of 
100%. 
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4.3.6 BNP concentration and 6 week all cause mortality 
The median pre-operative BNP level (pg/ml) was significantly higher in those patients 
who died within 6 weeks of surgery (155.5 (46-781) vs. 32 (11-82) (p=0.001). 
A BNP level of greater than 108.5pg/ml was a good predictor of all cause mortality 
(sensitivity- 57.1%, specificity- 82.2%, ppv- 25.8%, npv- 94.9%); however a level of 
86.5 had the best combined sensitivity and specificity (sensitivity- 71.4%, specificity- 
77.8%, ppv- 25.0%, npv- 96.3%). 
 
4.3.7 Cardiac events in patients with a “low” BNP concentration (<108.5pg/ml) 
Only 2 of the patients who suffered a cardiac event had a “low” BNP (31 and 47pg/ml). 
Both had non-fatal events, one occurring at 48hrs (following aortic tube graft) and one at 
4 weeks (following amputation). Although both had risk factors for ischaemic heart 
disease, there were few similarities to explain the occurrence of an event in the presence 
of a “low” BNP. One patient suffered from ischaemic heart disease, cerebrovascular 
disease and experienced intra-operative hypotension (RCRI- 3, Eagle- 1). The other had 
non-insulin dependent diabetes mellitus, hypertension, hyperlipidaemia and documented 
heart failure (RCRI- 1, Eagle- 2). 
 
4.3.8 Resting echocardiography and outcome 
10 patients underwent resting echocardiography (up to 6 months) pre-operatively. These 
were not requested as part of the study protocol. Left ventricular function was described 
as poor in 1 patient who suffered a cardiac event (BNP=1217). Three patients had 
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moderate left ventricular function and 6 had good ventricular function. None of these 9 
patients suffered a cardiac event.  
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4.4 Discussion 
This is the first prospective study to have demonstrated a clear correlation between pre-
operative plasma BNP concentration and cardiac risk employing strict, objective and 
clinically relevant end-points. It has shown that the pre-operative BNP concentration is 
consistently a sensitive and specific predictor of cardiac events which predicts outcome 
irrespective of clinical risk factors, and also discriminates between fatal and non-fatal 
events.  
 
Using ROC curve analysis in the validation cohort, a BNP level of 108.5pg/ml was 
identified as being the optimal cut-off point for the prediction of cardiac events. This 
level was also highly predictive of outcome in the derivation (pilot) cohort and levels 
above this may predict a poor cardiac outcome necessitating a change in the treatment 
plan. The majority (79%) of patients in the study had a pre-operative BNP concentration 
of less than 108.5pg/ml and therefore could proceed to surgery without any change in 
their treatment plan. Although the threshold concentration of BNP at which management 
should be changed is still not absolutely clear, and may vary depending on the 
population, our results would suggest that below 108.5pg/ml the likelihood of a cardiac 
event is low whereas above this level there is substantial risk. Above 180pg/ml the 
likelihood of a cardiac event increases further, being greater than 50% in this study. 
 
In this cohort, BNP concentration was also found to be a significant predictor of all cause 
6-weekly mortality. It is interesting that the best performing cut-off value for this end-
point was a BNP level of 86.5pg/ml, which is lower than that which best predicted the 
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occurrence of cardiac events. Patients with a low BNP concentration suffering a non-
cardiac death probably explain this phenomenon. 
 
BNP is a sensitive and specific predictor of left ventricular systolic dysfunction 
(McDonagh et al. 1998) and a level of 100 pg/ml has been shown to have a diagnostic 
accuracy of 83.4 % for the diagnosis of heart failure (Maisel et al. 2002). Heart failure is 
an important predictor of poor post-operative cardiac outcome (Shaw et al. 1996), and 
this may partly explain the predictive ability of the assay. Although pre-operative BNP 
concentration unsurprisingly reflected the presence of heart failure, heart failure itself 
was not found to be a significant predictor of cardiac outcome.  
 
BNP levels have been shown to predict both death and cardiovascular events in the 
community (McDonagh et al. 2004;Wang et al. 2004b). The BNP concentration that was 
predictive of poor outcome in those cohorts (17.9pg/ml and 20pg/ml) was much lower 
than the critical values found in this study and those used in the diagnosis of heart failure, 
however this is partly explained by the use of a different BNP assay. One other study has 
prospectively evaluated the relationship between BNP concentration and outcome. This 
was conducted in patients scheduled for cardiac surgery (Hutfless et al. 2004). They 
found a BNP concentration of >385pg/ml to be associated with complications and death, 
reflecting the unstable cardiac status of this population. Only one study has analysed the 
value of BNP measurement in the prediction of cardiac events following non-cardiac 
surgery (Yeh et al. 2005). This retrospective study of the BNP precursor, N-terminal 
proBNP, found that all patients suffering a cardiac complication had a serum 
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concentration greater than 450ng/l, with this concentration having a sensitivity of 100% 
and a specificity of 82.9% for the prediction of events. However the study was limited by 
the retrospective design, its use of subjective outcome measures and failure to screen for 
cardiac events (Gibson, Berry, & Kingsmore 2005). 
 
A number of different methods have been used to aid pre-operative cardiac risk 
stratification. Clinical scoring systems such as those devised by Eagle (Eagle et al. 1989) 
and Lee  (Lee 1999b) allow some objectivity but lack predictive ability for the individual 
patient. In the present study the RCRI showed some discriminatory ability, however a 
disproportionate number of patients with a score of 0 had an event. This may be related to 
the definition of lower extremity amputation as “infra-inguinal vascular surgery” which is 
considered as low risk of surgery in the RCRI. Other modalities such as trans-thoracic 
echocardiography (TTE) are commonly employed as an aid to pre-operative decision-
making. TTE delivers information on global and regional ventricular function as well as 
valvular abnormalities, and has been found to provide independent information about the 
risk of postoperative cardiac complications (Rohde et al. 2001). However some 
investigators have found that echocardiographic data adds little to clinical information 
alone, particularly when only objective end-points are studied (Halm et al. 1996). In 
addition, BNP has been found to be superior to resting echocardiography in the diagnosis 
of congestive heart failure (Steg et al. 2005). Cardiac stress testing has consistently 
identified those patients who will be free from cardiac events with high negative 
predictive values (Das et al. 2000;Poldermans et al. 1993). However it is expensive, time 
consuming and has shown poor positive predictive ability, even in high risk cohorts (Das 
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et al. 2000). Despite guidelines on its use being produced (Eagle et al. 1996b), the 
appropriate role of cardiac stress testing in this setting is still unknown (Morgan et al. 
2002). 
 
A variety of options exist for the surgical patient judged at high risk. In some cases, such 
as in elective aortic aneurysm repair, the surgery may be cancelled or postponed. In other 
cases where surgery is deemed essential, patients’ cardiac status should be optimised. The 
benefits of coronary intervention in this group have been questioned (McFalls et al. 
2004); however the prescription of beta-blockers, statins and the use of appropriate 
anaesthetic techniques such as thoracic epidurals may reduce morbidity (Kertai et al. 
2004a;Yeager et al. 1987).  
 
In conclusion, BNP measurement is a simple, practical test that provides important 
prognostic information in the pre-operative population. It outperforms conventional 
clinical risk scoring strategies and has a similar predictive ability to more complex, time 
consuming and expensive tests (Das et al. 2000;Poldermans et al. 1993). BNP shows 
great promise in identifying patients at high risk of cardiac complications in whom 
consideration should be given to a modified treatment plan. 
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5. Should pre-operative troponin be a 
standard requirement in patients undergoing 
major   lower extremity amputation? 
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5.1 Introduction 
 
Patients requiring lower extremity amputation have a high associated peri-operative risk, 
with reported 30 day mortality rates of up to 17% (Cruz et al. 2003). The most common 
cause of death after surgery is MI (Aulivola et al. 2004), supporting the results of 
pathological studies which report that up to 92% of patients with peripheral arterial 
disease significant enough to warrant amputation have diffuse and severe coronary artery 
atherosclerosis (Mautner et al. 1992).  
 
Cardiac troponin I (cTnI) is a contractile protein that is released into the circulation after 
myocardial cell injury. It is not found in skeletal muscle and is therefore a sensitive and 
specific marker of myocardial necrosis and cardiac events (Adams et al. 1993;Apple et al. 
1997). Whilst a raised post-operative level of cTnI has been found to correlate with all 
cause mortality in vascular surgical patients (Higham et al. 2004;Kertai et al. 2004a;Kim 
et al. 2002;Tambyraja et al. 2005), there are only isolated reports of an association 
between elevated pre-operative cTnI and the risk of cardiac events or death (Hobbs et al. 
2005). Most studies of outcome specifically exclude patients on the basis of an elevated 
pre-operative cTnI (Higham et al. 2004) or do not include its measurement in their 
protocol (Kertai et al. 2004a;Kim et al. 2002). The aim of this study was to ascertain the 
benefit of routine pre-operative cTnI measurement in vascular surgery, in particular in 
lower extremity amputation patients. 
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5.2 Patients and Methods 
 
5.2.1 Patients 
Initially, all patients undergoing major vascular surgery in a single vascular surgery 
department were considered for inclusion in the study, however in the pilot cohort of 41 
patients there was only one case of an elevated pre-operative cTnI. This was in a patient 
scheduled for lower extremity amputation. A decision was therefore made to focus on 
this particularly high-risk group of patients with patients from the pilot study being 
included.   
 
All patients scheduled for major lower extremity amputation were therefore prospectively 
identified between April 2004 and April 2005. Clinical variables and medications 
prescribed were recorded, and the Eagle score calculated for each patient (Eagle et al.  
1989). Procedures were classed urgent if they were conducted on the same admission as a 
referral from the emergency department or another source. Procedures were considered 
elective if patients were admitted from home for treatment. Patients were excluded if 
there was clinical evidence of unstable coronary artery disease (cardiac chest pain or 
ischaemic ECG changes) at the time of pre-operative evaluation, if the surgery was 
performed as an emergency (<24 hours) or if informed consent could not be obtained. 
Local research ethics committee approval was obtained for this study. 
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5.2.2 Sample collection and analysis 
Pre-operative venous blood samples were collected on the evening prior to surgery in 
sterile lithium heparin tubes. Serum cTnI was measured using the ADVIA Centaur® 
immunoassay (Bayer Diagnostics), which has a sensitivity and assay range of 0.1-
50ng/ml. Results of the cTnI assay, performed exclusively as part of this study and not 
requested by clinicians, were not released to treating clinicians. Routine pre-operative 
investigations were conducted at the discretion of anaesthetic and surgical staff. 
 
5.2.3 Study end points 
The study end points were non-fatal MI, and cardiac death. The definition of MI was that 
of The Joint European Society of Cardiology/American College of Cardiology 
Committee. Cardiac death was determined by a review of all post-operative data by 2 
cardiologists who were blinded to pre-operative cTnI levels. Patients were followed up 
for six weeks after surgery. 
 
5.2.4 Post-operative detection and interpretation of cardiac events 
Post-operative screening for cardiac events consisted of daily clinical assessment, serial 
electrocardiography and cTnI measurement (postoperative days 2, 5 and 42). The results 
of these tests were circulated to the responsible clinicians. Other investigations were 
conducted as clinically indicated. ECG analysis was performed, in a batch at the end of 
the study period, by 2 cardiologists blinded to all other data and patient details. A 
separate independent clinician reviewed 10% of all ECGs, clinical notes and data analysis 
to ensure quality control.  
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5.2.5 Statistical analysis 
Statistical analysis was conducted using SPSS® statistical software package (SPSS, 
Chicago, Illinois, USA). Values are reported as median (range). Univariate analyses 
between groups were conducted using a two tailed Fisher’s exact test. Continuous 
variables were compared using a Mann-Whitney test. A probability value of less than 
0.05 was considered statistically significant. 
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5.3 Results 
 
5.3.1 Population 
During the 1-year period, a total of 44 patients underwent major lower extremity 
amputation and were included in the study. The indication for operation in all cases was 
critical lower limb ischaemia.  Of the forty-four patients included, 28 were male and 16 
were female. The median age was 71 (41-91) years (Table 1). Thirty-two patients 
underwent a below knee amputation and twelve an above knee amputation, all as primary 
procedures. Co-morbidity was common: ischaemic heart disease (15); medically treated 
diabetes mellitus (19); chronic obstructive airways disease (9); cerebrovascular disease 
(10); renal impairment (pre-operative creatinine >130mmol/l) (12); hyperlipidaemia (24); 
hypertension (33). Some twenty-four patients were prescribed statins and 9 were 
prescribed beta-blockers peri-operatively.  The median Eagle score was 2 (range 0-4). 
Twelve procedures were urgent and 32 were elective.  
 
In total there were 2 amputation stump infections and one traumatic haematoma. One 
patient suffered a chest infection and one a transient ischaemic attack post-operatively. 
 
5.3.2 Post-operative cardiac events 
There were 10 post-operative cardiac events: 5 non-fatal MIs and 5 cardiac deaths. Three 
of the non-fatal MIs were symptomatic and occurred within 48 hours of the procedure. 
Two were clinically silent and were diagnosed by screening (days 2 and 5 post-
operatively). Of the 5 cardiac deaths, one followed an intra-operative cardiac arrest, the 
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other 4 being secondary to myocardial infarction. Two of the fatal MIs were diagnosed 
clinically and both patients died within 2 weeks of the procedure. Two were detected by 
screening on day 5, and these patients died following progression of heart failure in 
weeks 4 and 5 respectively.      
 
The median age of those patients having an event was 76.5 (41-91) compared with 71 
(54-86) in those who were event free (p=0.503). Post-operative cardiac events were more 
common in patients who had renal impairment, underwent an urgent procedure or had an 
Eagle score of greater than 1. Events were less likely in patients prescribed statins or 
beta-blockers. There was no difference in post-operative cardiac event rates in patients 
with a history of ischaemic heart disease (Table 5.1). 
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Table 5.1 Post-operative cardiac outcome by risk factors 
 
  Cardiac 
Event 
No Cardiac 
Event 
 
 
 
 
Risk Factor  n     n     (%)     n     (%) p* 
 
     
Sex Male   28     6   (21%)     22   (79%)   1.000 
 
Female   16     4   (25%)     12   (75%)  
 
     
Ischaemic Heart 
        Disease  
Yes  
No 
  15 
  29 
    3   (20%)  
    7   (24%) 
    12   (80%)  
    22   (76%) 
  1.000 
 
     
Diabetes Mellitus Yes   19     5   (26%)     14   (74%) 0.723 
 
No   25     5   (20%)     20   (80%)  
 
     
COPD  Yes     9     2   (22%)       7   (78%) 1.000 
 
No   35     8   (23%)     27   (77%)  
 
     
Cerebrovascular 
      Disease  
Yes  
No 
  10  
  34 
    2   (20%)  
    8   (24%) 
      8   (80%) 
    26   (76%) 
1.000 
 
     
Renal Impairment Yes   12      4   (33%)       8   (67%) 0.422 
 
No   32      6   (19%)     26   (81%)  
 
     
Beta Blocker  Yes     9     1   (11%)       8   (89%) 0.659 
 
No   35     9   (26%)     26   (74%)  
 
     
Statin  Yes   24     3   (12%)     21   (88%) 0.147 
 
No   20     7   (35%)     13   (65%)  
 
     
Urgent Procedure  Yes   12     4   (33%)       8   (67%) 0.422 
 
No   32     6   (19%)      26 (81%)  
 
     
Eagle > 1 Yes   24     7   (29%)      17 (71%) 0.306 
 
No   20     3   (15%)      17 (85%)  
 
     
Amputation level BKA   32     6   (19%)      26 (81%) 0.422 
 AKA   12     4   (33%)        8 (67%)  
 
     
Elevated cTnI Yes     3     3 (100%)       0   (0%) 0.009 
 
No   41     7   (17%)     34   (83%)  
 
     
Total    44   10     34  
 
 
p*- Fisher’s exact test 
cTnI – Cardiac troponin I 
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5.3.4 Raised pre-operative troponin 
Pre-operative cTnI was raised in three patients (0.8, 0.3, 14.8ng/ml), all of whom 
underwent an urgent procedure (Table 5.2). In no patients was the pre-operative ECG 
identified as indicating acute myocardial injury. Whilst none of the patients were 
prescribed statins pre-operatively, there were no other consistent clinical variables. All 3 
patients had post-operative cardiac events with 2 deaths and 1 non-fatal MI. There was no 
correlation between cTnI level and severity of event. Patient 1 (pre-operative 
cTnI=0.8ng/ml) suffered a fatal MI, dying on day 10 post-operatively. Patient 2 (pre-
operative cTnI=0.3ng/ml) suffered a fatal intra-operative cardiac arrest. Patient 3 (pre-
operative cTnI=14.8ng/ml) suffered an MI on day 2 post-operatively, diagnosed using 
clinical and ECG criteria. This patient was discharged home 4 weeks post-operatively. 
 
Although there were few clinical variables consistent between the 3 patients, when other 
markers were analysed there was an association, as all 3 patients, in addition to having a 
raised cTnI, had high BNP and CRP concentrations. 
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Table 5.2 Co-morbidity and outcome in patients with a raised pre-operative cardiac 
troponin I 
 
 
Patient 1 2 3 
 
     
 
     
 
     Pre-op Troponin (ng/ml) 0.8 0.3 14.8 
 
     
 
     
Pre-op Creatinine (µmol/l) 
 
Pre-op BNP (pg/ml) 
 
Pre-op CRP (mg/l) 
126 
 
263 
 
260 
172 
 
1034 
 
102 
50 
 
1111 
 
           204 
 
     
 
     
Ischaemic Heart Disease Yes Yes No 
 
     
 
     
Diabetes Mellitus Yes Yes No 
 
     
 
     
COPD No Yes No 
 
     
 
     
Cerebrovascular Disease Yes No Yes 
 
     
 
     
Beta-Blocker No Yes No 
 
     
 
     
Statin No No No 
 
     
 
     
Urgent Procedure Yes Yes Yes 
 
     
 
     
Eagle Score 3 4 0 
 
     
 
     
 
     Outcome Cardiac death Cardiac death Non-fatal MI 
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5.4 Discussion 
In this study of patients undergoing major lower extremity amputation for critical limb 
ischaemia, pre-operative cTnI was elevated in 7% of cases and was associated with a 
very poor outcome. Whilst the absolute number of patients recruited was small, the rigid 
entry criteria ensured a homogeneous, stable population with consistent surgical and 
anaesthetic techniques, without selection bias, and whose follow up was complete. The 
study also employed objective end-points that were clinically relevant.  
   
Previous studies of patients undergoing amputation have found high associated co-
morbidity and a high cardiac complication rate  (Cruz et al. 2003). In this study of 44 
patients, there were 9 post-operative MIs, 4 of which were silent and only detected by the 
post-operative screening protocol. Five patients died of cardiac causes within 6 weeks of 
the procedure. Major lower extremity amputation patients therefore represent a 
particularly high-risk group. Knowledge of the pre-operative cTnI might influence peri-
operative support and anaesthetic techniques. 
 
The number of patients in this study prescribed beta blockers and statins was 
disappointingly low given the published evidence concerning their role in the prevention 
of peri-operative cardiac events (Kertai et al. 2004b;Poldermans, Boersma et al. 1999). 
However this lower than expected prescription rate is consistent with other published 
evidence such as a recent survey of Canadian anaesthetists (VanDenKerkhof et al. 2003). 
Whilst the numbers in the present study were small, it is interesting to note that the 
cardiac event rate was 50% lower in patients prescribed statins or beta-blockers. This 
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may relate to the effect of the drugs, more aggressive investigation in this group, or may 
reflect more stable coronary artery disease in these patients.  
 
The most important clinical risk factors in determining the occurrence of post-operative 
cardiac events were an urgent procedure and the presence of renal impairment. Patients 
with an Eagle score of greater than 1 were also more likely to suffer an event. Although 
none of these factors reached statistical significance, this probably reflects the small 
numbers in each group. Interestingly there was no correlation between a history of 
ischaemic heart disease and outcome despite the use of the definition established by Lee 
et al (Lee et al. 1999a). This finding may be explained by the high frequency of occult 
coronary artery disease in patients with peripheral vascular disease (Mautner et al. 1992). 
The simplistic allocation of cardiac disease into symptomatic and asymptomatic may not 
be valid in this cohort. 
 
Myocardial infarction after surgery is more often silent than symptomatic (Badner et al. 
1998).  In this study, one-half of post-operative MIs were clinically asymptomatic. Post-
operative MI is associated with a poor prognosis and those patients with an asymptomatic 
rise in post-operative troponin have been shown to have a poorer outcome at 1 year 
(Kertai et al. 2004a). Therefore, routine post-operative screening for cardiac events may 
be beneficial to identify these high-risk patients, allowing appropriate cardiac assessment.   
 
Pre-operative cTnI was raised in 3 patients in whom it was a universally poor prognostic 
marker (2 cardiac deaths, 1 non-fatal MI).  Interestingly there was no correlation between 
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the level of cTnI rise and severity of outcome. Few studies have reported the role of pre-
operative cTnI measurement, and those that have done so confirmed these findings. 
Hobbs et al (2005) studied peri-operative cTnI in patients with critical limb ischaemia and 
described 2 patients who had an elevated pre-operative level: one sustained a fatal intra-
operative cardio-pulmonary arrest while the other had a markedly raised post-operative 
troponin and developed acute congestive heart failure. The only common factors amongst 
the three patients with a raised preoperative cTnI in this study were the urgency of their 
procedure, the failure of prescription of statins and high levels of both BNP and CRP.  
 
In summary, this study confirms that routine preoperative cTnI testing could be used to 
identify patients in whom a poor outcome is likely. For these patients it may be preferable 
to defer surgery allowing cardiac investigation and optimisation (Kertai et al. 2004b). In 
some cases, surgery cannot be delayed since the tissue ischaemia and necrosis is the 
cause of the cardiac stress. In this event the presence of a senior anaesthetist and surgeon 
as well as high dependency care, cardiac optimisation and haemodynamic monitoring 
post operatively may reduce risk. 
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6. C-reactive Protein (CRP) As A Prognostic Marker In 
Patients Undergoing Major Vascular Surgery 
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6.1 Introduction 
Cardiac morbidity remains a major problem associated with vascular surgery despite 
measures to reduce risk (Kertai et al. 2003b). As atherosclerosis is a systemic disease, 
patients scheduled for vascular surgery are predisposed to having coronary artery disease 
with haemodynamically significant lesions present in up to 36% of patients (Hertzer et al. 
1984). 
 
Atherosclerosis is also now thought to be an inflammatory process, with inflammation 
coupling dyslipidaemia to atherogenesis. (Libby 2002;Willerson & Ridker 2004) As a 
consequence, of this inflammatory markers have been investigated as predictors of 
cardiac outcome. The non-specific acute-phase reactant C-reactive protein (CRP) has 
shown particular promise in this regard with raised serum concentrations increasing the 
odds of patients suffering a myocardial infarction in the short and long term (Haverkate et 
al. 1997;Sakkinen et al. 2002). CRP levels have been analysed specifically in critical limb 
ischaemia patients and have predicted cardiac morbidity and mortality at 1 year follow-up 
in both surgical and non-surgical cohorts (Barani et al. 2005;Rossi et al. 2002). 
 
The aim of this study was to determine if there was an association between pre-operative 
CRP concentration and short-medium term cardiac outcome in patients undergoing major 
vascular surgery.  
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6.2 Patients and Methods 
6.2.1 Patients 
All patients scheduled for major vascular surgery in a single centre over an 18 month 
period were eligible for inclusion. Patients in this study had participated in the studies 
assessing the predictive value of BNP concentration. Patients were excluded if they were 
unable to give informed consent or if their surgery was emergency (<24 hours of 
admission). Local research and ethics committee approval was obtained for this study. 
 
6.2.2 Sample collection and analysis 
Serum CRP was collected and analysed along with routine pre-operative bloods on the 
day prior to surgery. CRP was determined with the Abbott assay (Abbott diagnostics) 
which has a sensitivity of 0.5mg/l. Routine pre-operative investigations were conducted 
at the discretion of surgical and anaesthetic staff. 
 
6.2.3 Data Collection 
Basic demographic data and factors relating to the cardiac risk of surgery were 
prospectively gathered for each patient. These included: clinical variables, medications 
prescribed, and intra-operative details. Ischaemic heart disease (IHD) and heart failure 
were classified using established definitions (Lee et al. 1999b;Swedberg et al. 2005). 
Renal impairment was defined as a pre-operative creatinine of greater than 130µmol/l 
and intra-operative hypotension as a systolic blood pressure of less than 90mmHg for 
more than 5 minutes during surgery.  
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6.2.4 Study end-points 
The end-points for the study were non-fatal myocardial infarction and cardiac death. The 
definition of myocardial infarction was that of The Joint European Society of 
Cardiology/American College of Cardiology Committee. Cardiac death was defined as 
death secondary to myocardial infarction, cardiogenic shock or intractable dysrhythmia, 
and was determined by a review of post-operative data by 2 cardiologists who were 
blinded to pre-operative CRP levels. Patients were followed up for six weeks after 
surgery. 
 
6.2.5 Post-operative detection and interpretation of cardiac events 
Post-operative screening for cardiac events consisted of daily clinical assessment, serial 
electrocardiography and cardiac troponin I measurement on post-operative days 2, 5 and 
42. Other investigations were conducted as clinically indicated. ECG analysis was 
performed by 2 cardiologists blinded to all other data and patient details, in a batch at the 
end of the study period. In a random sample of 10% of patients, ECGs, clinical notes and 
data entry was analysed separately in order to ensure quality control.  
 
6.2.6 Statistical analysis 
Statistical analysis was conducted using SPSS® statistical software package (SPSS, 
Chicago, Illinois, USA). Univariate analysis between groups was conducted using 
Pearson’s chi-square test or a two-tailed Fisher’s exact test. Continuous variables were 
compared using a Mann-Whitney test. Values are reported as median (interquartile 
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range). ROC curves were created to determine the relationship between CRP and cardiac 
events. 
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6.3 Results 
6.3.1 Population  
124 patients (86 males and 38 females) were recruited to the study over the 18 month 
period. Cardiac co-morbidity was common: ischaemic heart disease (44); heart failure 
(30). Some 55 patients were prescribed a statin and 22 a beta blocker. The case-mix is 
shown in table 6.1. Patients underwent aortic surgery (36), peripheral bypass surgery (51) 
and lower extremity amputation (37). Further operative factors are shown in table 6.1 
 
6.3.2 Cardiac events 
Some 21 patients (17%) suffered a cardiac event. These consisted of 12 non fatal 
myocardial infarctions and 9 cardiac deaths. Thirteen events (62%) occurred in the first 
48 hours, 5 from 48 hours to 1 week (24%) and 3 (14%) between 1 and 6 weeks. Cardiac 
events were more common in patients with a history of cardiovascular, cerebrovascular 
or renovascular disease, although none of these were significant predictors of outcome. 
The event rate was lower in patients prescribed statins but not beta-blockers. Urgency of 
procedure (within the same stay as an emergency admission/referral) and type of 
procedure were the only operative factors which significantly impacted on outcome, 
although the cardiac event rate was higher if patients had sustained intra-operative 
hypotension (Table 6.1). 
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Table 6.1 Risk factors and the cardiac event rate 
 
  Cardiac 
Event 
No  
Cardiac 
Event 
p Risk Factor 
 n n (%)  
Sex Male  86   15 (17.4)     71 (82.6) 1 
 
Female  38     6 (15.8)     32 (84.2)  
 
     Ischaemic Heart Disease Yes  44 
  
  10 (22.7) 
   
    34  (77.3) 
 
0.219 
 
No  80 11 (13.8)    69  (86.2)  
 
     Heart Failure Yes  30       8  (26.7)     22  (73.3) 0.159 
 
No  94  13  (13.8)     81  (86.2)  
 
     Diabetes Mellitus Yes  32    8  (25.0)     24  (75.0) 0.177 
 
No  92  13  (14.1)     79  (85.9)  
 
     COPD  Yes  27      3  (11.1)     24  (88.9) 0.562 
 
No  97  18  (18.6)     79  (81.4)  
 
     Cerebrovascular Disease Yes 14 
 
   4  (28.6) 
  
    10  (71.4)   
 
0.254 
 
No 110 17  (15.5)    93  (84.5)  
 
     Renal Impairment Yes 17    4  (23.5)     13  (76.5) 0.487 
 
No  107  17  (15.9)     90  (84.1)  
 
     
Beta Blocker  Yes    22     5  (22.7)     17  (77.3) 0.530 
 
No  102  16  (15.7)     86  (84.3)  
 
     Statin  Yes  55    9  (16.4)     46  (83.6) 0.815 
 
No  69  13  (18.8)     56  (81.2)  
 
     
Urgent Procedure  Yes  11    6  (54.5)       5  (45.5) 0.028 
 
No 113  15  (21.1)      98 (78.9)  
 
     
Surgery Aortic 36    5  (13.8)      31 (86.2) 0.008 
 
Bypass 51    4    (7.8)      47 (92.2)  
 
Amputation 37  12  (32.4)      25 (67.6)  
 
     Intraop hypotension Yes 27    7  (25.9)      20 (74.1) 0.243 
 
No 97  14  (14.4)      83 (85.6)  
 
     Blood Loss <500mls 93  18  (19.4)      75 (80.6) 0.276 
 
500+mls 31    3    (9.7)      28 (90.3)  
 
     Operation time <2hrs 61  12  (19.7)      49 (80.3) 0.479 
 
2+hrs 63    9  (14.3)      54 (85.7)  
 
     
Eagle score 0 57    3     (5.3)      54 (94.7)  
 
1-2 58   13   (22.4)      45 (77.6)  
 
3+ 9    5    (55.6)        4 (44.4) <0.001 
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6.3.3 Inflammatory markers and cardiac outcome 
The median CRP (mg/l) was 16 (5-75). The median CRP in those patients who had a 
cardiac event was significantly higher than those who did not: 69 (17-205) vs. 12 (5-55), 
(p=0.003) (Figure 6.1).  
 
 
Figure 6.1 CRP and the cardiac event rate 
 
 
 
ROC curve analysis was conducted (figure 6.2) with the area under the curve being 
0.704. A CRP of 20mg/l was the best performing cut-off having a sensitivity of 71.4% 
and a specificity of 62.1%  
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 Figure 6.2 ROC curve: CRP and cardiac events 
1.00.80.60.40.20.0
1 - Specificity
1.0
0.8
0.6
0.4
0.2
0.0
Se
n
si
tiv
ity
ROC Curve
Diagonal segments are produced by ties.
 
 
The cardiac event rate rose between each CRP tertile, although there was only a trend to 
significance (p= 0.057) (Table 6.2). However with each logarithmic increment in CRP 
the cardiac event rate changed significantly: 0-10mg/l (5.7%); 11-100mg/l (22.4%), 
>100mg/l (55.6%) (p=0.002), (Figure 6.3, Table 6.3).  
 
The median white cell count (WCC) was 9.4 (7.4-12.0). The median WCC in those 
patients who had an event was higher than in those who did not: 10.9 (9.9-12.0) vs. 8.7 
(7.1-12.0) (p=0.008). Some 15 of 92 (16.3%) patients with a WCC of less than 12 had a 
cardiac event compared with 6 of 32 (18.8%) patients whose WCC was 12 or greater 
(p=0.787), (Table 6.2). 
 
 
 141 
 
 
Table 6.2 CRP tertiles and the cardiac event rate 
 
 
 
Table 6.3 CRP and the cardiac event rate 
 
 
 
 
 
 
 
 
 
 
Inflammatory 
marker 
 n Cardiac 
Event 
No Cardiac 
Event 
p 
 
     
CRP tertile 0-6 42    3     (7.1)      39    (92.9)  
 
7-44 41    7     (17.1)      34    (82.9)  
 
>44 41    11   (26.8)      30    (73.2)   0.057 
 
     
WCC (109) 4-12 92   15    (16.3)      77    (83.7)  
 
>12 32    6     (18.8)      26    (81.3)   0.787 
 
     
Total  124    
Inflammatory 
marker 
 n Cardiac 
Event 
No Cardiac 
Event 
p 
 
     
CRP (mg/l) 0-10 53    3     (5.7)      50    (94.3)  
 
11-100 48    9     (18.8)      39    (81.2)  
 
>100 23    9     (39.1)      14    (60.9) 0.002 
 
     
 
     
Total  124    
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Figure 6.3 CRP and the cardiac event rate by logarithmic increment 
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The correlation between CRP and cardiac outcome varied depending on the category of 
vascular procedure conducted. In patients who underwent an aortic operation the cardiac 
event rate rose with each increment in CRP concentration. However this relationship did 
not hold in the amputation and peripheral revascularisation groups. Although in 
peripheral bypass patients the event rate rose markedly between the first 2 categories, 
none of the 4 patients with a CRP (mg/l) of greater than 100 had an event. Similarly, in 
the amputation group, although patients with a CRP (mg/l) of greater than 100 had a 
much higher event rate than those with a level of 11-100, 1 of the 3 patients with a CRP 
of less than 10 did suffer a cardiac event (Table 6.4). 
 
CRP concentration was associated with cardiac outcome irrespective of the presence of 
ischaemic heart disease. The cardiac event rate rose with each increment in CRP whether 
IHD was present or absent (Table 6.4). 
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Table 6.4 CRP and cardiac events by procedure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CRP(mg/l) Cardiac  
Events 
 
%  p 
Aortic Procedure 0-10 1/18 5.6  
 
11-100 3/16 18.8  
 
>100      1/2 50.0 0.170 
 
    
Peripheral bypass 0-10 1/32 3.1  
 
11-100 3/15 20.0  
 
>100 0/4 0.0   0.111 
 
    
Amputation 0-10 1/3 33.3  
 
11-100 3/17 17.6  
 
>100 8/17 47.1 0.187 
 
    
IHD present 0-10 1/34 2.9  
 
11-100 4/29 13.8  
 
>100 6/17 35.3 0.007 
 
    
IHD absent 0-10 2/19 10.5  
 
11-100 5/19 26.3  
 
>100 3/6 50.0 0.117 
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6.4 Discussion 
This study confirms the high incidence of cardiac complications in patients undergoing 
vascular surgery consistent with the systemic nature of atherosclerosis. Cardiac events 
occurred more commonly in patients with a history of cardiac, renal or cerebrovascular 
disease, although the only clinical factors which were significant predictors of cardiac 
outcome were urgency and type of procedure. The clinical scoring system developed by 
Eagle  (Eagle et al. 1989), which incorporates 5 clinical factors was highly predictive of 
cardiac events consistent with previous studies (Back et al. 2003;Poldermans et al. 1995). 
 
C-reactive protein concentration was significantly predictive of outcome, with increasing 
cardiac event rates with each logarithmic increment. A trend to significance was 
demonstrated between CRP tertiles. Both CRP concentration and WCC were 
significantly higher in those patients who suffered a cardiac event compared with those 
who did not. The cardiac event rose with each increment in CRP whether ischaemic heart 
disease was present or absent. When different procedures were considered, the 
correlation between CRP concentration and cardiac events was most consistent in the 
aortic group, possibly because in this group the CRP concentration was least likely to be 
raised as a consequence of peripheral sepsis. A raised level in these patients may have 
been more likely to represent systemic atherosclerosis. 
 
CRP concentration has been shown to predict coronary events in patients with pre-
existing cardiac disease in the medium and long term (Sakkinen et al. 2002). Levels have 
been associated with the likelihood of developing peripheral vascular disease (Ridker et 
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al. 1998) and found to be inversely proportional to the ABPI (Vainas et al. 2005). 
Furthermore femoral plaques have been demonstrated to produce CRP (Vainas et al. 
2005). CRP concentration has been correlated with cardiac outcome at 24 months 
following vascular surgery, with concentrations in the upper tertile predicting 60% of 
myocardial infarctions (Rossi et al.2002). In addition, in their study of 259 patients with 
critical limb ischaemia, Barani et al found the mean CRP in those patients who suffered a 
fatal event was significantly higher than those who survived (49.4 vs. 33.6, p= 0.02), 
although when the presence or absence of gangrene was taken into account the difference 
was no longer significant (Barani et al. 2005). No studies to date have correlated CRP 
concentration with peri-operative cardiac complications. 
 
This study has demonstrated a correlation between CRP concentration and cardiac 
outcome following vascular surgery. Whilst this may reflect systemic inflammation, 
raised levels due to coronary atherosclerosis would also explain the relationship. 
Furthermore the correlation between CRP and cardiac outcome was most noticeable in 
aortic surgery patients, the group in whom peripheral sepsis was least likely. 
CRP is a relatively inexpensive and routine test. Measurement prior to vascular surgery 
may be of benefit in predicting the likelihood of peri-operative cardiac events, but may 
also be of use as a target for reducing the event rate by modulating the inflammatory 
response. 
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7.1 Limitations of the thesis 
An attempt was made to make the work in this thesis as robust and comprehensive as 
possible, however there were limitations. Although adequately powered to demonstrate 
significant differences between the primary variables studied, the small sample-size was 
an issue and precluded multivariate analysis in all but chapter 4. Even in this study 
however, the statistical model became unstable as additional factors were adjusted for, 
thus limiting the information gained.  
 
A differing approach to statistical analysis may also have been appropriate. Creatinine 
concentrations were dichotomised when they could have been better analysed as 
continuous variables. This may have led to a more accurate demonstration of the effect of 
pre-operative renal function on outcome. Furthermore the same cut-off values were used 
to discriminate an abnormal creatinine in males and females when ideally differing values 
for each sex would have been more appropriate. 
 
The predominant role of renal function in determining BNP levels could also have been 
better accounted for. In addition to the use of creatinine as a continuous variable in 
analysis, glomerular filtration rate could have been employed as a variable and would 
have been superior to the methods used. Unfortunately on initiation of the studies 
conducted in this thesis the current techniques for estimating GFR were not available. 
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7.2 Cardiac morbidity associated with surgery  
The findings of this thesis confirm that cardiac morbidity is still a major problem 
associated with general surgery and with vascular surgery in particular. Cardiac event 
rates were 6.6% in general surgical patients and ranged from 12.5% to 26.8% in vascular 
patients. Lower extremity amputation carried a particularly high risk consistent with the 
extreme nature of the atherosclerosis in these patients. Attempts to predict the occurrence 
of cardiac events in these cohorts and therefore improve the outcome post-surgery 
therefore continue to be relevant. 
 
This thesis does not deal with the nature of peri-operative myocardial infarction, but the 
prevalence of silent myocardial infarction (20-27% of events) was surprising although 
consistent with some studies (Badner et al. 1998;Raby et al. 1992). Screening for cardiac 
events detected silent myocardial infarctions and this almost certainly contributed to the 
higher event rates in the studies within this thesis. 
 
7.3 Timing of cardiac events 
The likelihood of a cardiac event was inversely proportional to the length of time from 
the operative stress. Peri-operative cardiac events occurred most commonly in the first 48 
hours (60-64%), with events from 48 hours to 6 weeks (20-27%) and from 1 week 
onwards (9-20%) being less likely. Screening for cardiac events would therefore be most 
useful immediately following surgery but if confined to this period would fail to detect 
some events. Screening may therefore also be of benefit for a period beyond the 
immediate post-operative phase. 
 149 
7.4 Clinical and operative factors and the cardiac event rate 
The cardiac event rate was universally higher in patients with established clinical risk 
factors. Heart failure, ischaemic heart disease, renal impairment, cerebrovascular disease 
and diabetes mellitus were consistently associated with poor cardiac outcome although 
none was a significant single predictor of cardiac events in any of the cohorts. 
Patients undergoing vascular surgery, particularly those scheduled for amputation were at 
highest risk of cardiac events reflecting the systemic nature of their atherosclerosis. This 
has been a consistent finding in studies assessing the risk of individual procedures 
(Detsky et al. 1986;Lee et al. 1999b). The single most important operative factor relating 
to outcome was the presence of intra-operative hypotension. Although not a significant 
predictor of outcome, its occurrence was consistently related to an increased cardiac 
event rate. This finding would support the theory that peri-operative myocardial 
infarctions are due to an imbalance in the supply and demand of oxygen related to the 
stress of surgery in the presence of coronary artery disease (Grayburn & Hillis 2003). 
Patients undergoing procedures classed as urgent were also at higher risk of a cardiac 
event. This may relate to the physiological condition of the patient, but also to the lack of 
opportunity for optimisation prior to the procedure. Surprisingly neither increased 
procedure time nor increased blood loss consistently affected the cardiac event rate in any 
of the studies described in this thesis. 
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7.5 Cardiac medications 
This thesis has not specifically addressed the benefits of beta-blockers or statins, however 
it is interesting that in the pilot BNP study (chapter 3), the cardiac event rate was lower in 
patients prescribed beta-blockers. This finding was however not replicated in the larger 
studies. This is perhaps unsurprising since those patients in whom beta blocker therapy 
was thought necessary by treating physicians would be more likely to have associated co-
morbidities predisposing them to cardiac events. The benefits of statin prescription are 
similarly difficult to interpret. In the validation BNP study, which analysed both general 
and vascular surgical patients (chapter 4), the cardiac event rate was higher in patients 
prescribed statins. However in the purely vascular cohorts and in particular when only 
amputation patients were considered, the event rate was lower in patients prescribed 
statins consistent with those studies reporting their cardio-protective role (Kertai et al. 
2004a;Poldermans et al. 2003). It may be that statin therapy is of most benefit in these 
higher risk patients. 
 
7.6 Clinical scoring systems 
The two main scoring systems studied and employed in this thesis are the Eagle score 
(Eagle et al. 1989) and the RCRI (Lee et al. 1999b). The Eagle score was consistently 
predictive of cardiac outcome in patients undergoing vascular surgery, being a significant 
predictor of outcome in both cohorts in which it was evaluated (chapters 3 and 6). 
Although it was not a significant predictor of outcome in the study analysing purely 
amputation patients (chapter 5) this may reflect the fewer numbers analysed. Despite 
being devised some years ago the Eagle score may be of benefit in pre-operative decision 
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making strategies.  As it was not designed to do so, the effectiveness of the Eagle score 
was not evaluated in non-vascular patients.  
 
The revised cardiac risk index has been validated in non-cardiac surgical patients (Lee et 
al. 1999b), however in the studies included in this thesis it was not discriminatory 
between the event rates in the lowest two risk categories, with a disproportionate number 
of patients with a score of 0 suffering an event. The likelihood of suffering a cardiac 
event did however increase between the three highest risk categories (8.2%, 9.5% and 
17.6%). In the original paper the RCRI performed better in those patients who underwent 
non-vascular surgery. However, when only non-vascular patients were considered in this 
thesis the predictive ability of the RCRI did not improve. This could be attributed to the 
smaller numbers analysed as only 4 patients were found to have an RCRI of 3 or more. 
Although the RCRI can provide additional prognostic information, on the evidence of 
this thesis it could not be used to determine a treatment plan for individual patients. 
 
7.7 B-type natriuretic peptide 
BNP concentration was consistently found to be a predictor of cardiac events, and 
mortality, although the optimal cut-off point varied depending on the cohort and the type 
of surgery conducted. In the pilot study (chapter 3), a BNP concentration of 123pg/ml 
was completely discriminatory for the prediction of cardiac events, whereas in the 
validation study, ROC analysis identified a BNP concentration of 108.5pg/ml as being 
the best cut-off, having the best combined sensitivity (87%) and specificity (87%) for the 
prediction of cardiac events. Whilst the optimal cut-off BNP concentration for patients 
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undergoing a non-vascular procedure in the validation study was also 108.5pg/ml, it was 
somewhat higher in the vascular patients with a level of 140.5pg/ml having a sensitivity 
of 82% and a specificity of 86%.  
 
The majority of patients in the studies in this thesis had a BNP concentration of less than 
108.5pg/ml and could therefore have their surgery expedited with no further intervention 
required. As only 21% of patients had a BNP concentration of greater than 108.5pg/ml 
(in the validation cohort, chapter 4) it is feasible that these patients could be more 
thoroughly investigated and better optimised prior to the proposed surgical procedure. 
This may be of benefit, particularly given the high cardiac event rate observed in these 
patients in the validation study. In patients with a BNP concentration of greater than 
180pg/ml the cardiac event rate exceeded 50%. This group therefore carry a significant 
risk of a cardiac event and a change in their treatment pathway is likely to be appropriate. 
 
The prognostic ability of BNP cannot be attributed to any other factor, as in a logistic 
regression model, logeBNP remained a highly significant predictor of cardiac events. 
Furthermore, in each category of the RCRI, BNP levels were higher in those patients who 
had a cardiac event. BNP concentration was highly predictive for cardiac events 
irrespective of the surgery performed and its measurement is therefore applicable to both 
vascular and general surgery populations. Measurement of BNP is a simple and practical 
test, with newer assays yielding results in 21 minutes. It outperforms conventional 
scoring systems (Lee 1999b) and has a similar predictive ability to more complex, time 
consuming and expensive tests such as DSE (Poldermans 1995).  
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Some 20% of patients in this study had a BNP concentration of greater than 108.5pg/ml 
and results from this study would suggest that in these patients it may be appropriate to 
consider a change in the treatment plan. Only 2 patients with a “low” BNP had a cardiac 
event and although both patients would be considered as at moderate or severe risk of a 
cardiac event by virtue of their other clinical factors, there were few similarities between 
the two. This reflects the multifactorial nature of peri-operative cardiac morbidity. 
 
Cardiac troponin I 
A pre-operative rise in cTnI is a rare phenomenon, both in this study and in those studies 
available in the literature (Higham et al. 2004;Hobbs et al. 2005). In the patients analysed 
in this thesis a rise occurred exclusively in patients scheduled for lower extremity 
amputation. Nonetheless it is a useful observation since these patients had a universally 
poor outcome (significant cardiac event or death). It may therefore be preferable to defer 
surgery in this group thus allowing the opportunity for cardiac optimisation. At the very 
least it should be ensured that operative stress is at a minimum with an experienced team 
being involved. Post-operatively, high dependency care for these patients may also be of 
benefit. 
 
C-reactive protein 
Consistent with previous studies, pre-operative CRP concentration correlated with 
cardiac outcome following vascular surgery (Barani et al. 2005;Rossi et al. 2002). The 
percentage of patients having a cardiac event increased with each logarithmic increment 
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in CRP (p=0.002) and also between tertiles (p=0.057). Whilst peripheral sepsis may have 
contributed to the elevated CRP level observed in some patients; coronary and systemic 
atherosclerosis is also likely to have influenced levels. It is particularly interesting that in 
the aortic surgery group (those patients least likely to have peripheral gangrene/sepsis) 
the observed relationship between cardiac events and CRP remained, suggesting that this 
particular group may benefit from further study. Measurement of CRP prior to vascular 
surgery may be of benefit in predicting the likelihood of peri-operative cardiac events, 
although its value may be limited by its non-specific nature. However it could also be of 
use as a marker in attempts to reduce the cardiac event rate by modulating the 
inflammatory response. 
 
Conclusion 
It has been suggested that the paradigm has shifted from predicting peri-operative cardiac 
events to their prevention (Grayburn, 2003). However with some doubt being cast over 
the initially promising measures to reduce the cardiac event rate (Devereaux et al. 2005), 
perhaps it is necessary to reconsider this. By careful case selection it may be possible to 
reduce the cardiac event rate and therefore the morbidity and mortality associated with 
surgery. Clinical scoring systems and biochemical markers such as CRP can give a guide 
to the likelihood of a cardiac event, but are not sufficiently predictive to alter the 
treatment plan. However pre-operative BNP concentration is a sensitive and specific 
predictor of outcome with predictive values sufficiently high to suggest that a change in 
the management plan for patients with raised level may be appropriate. Based on the 
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findings of this thesis BNP measurement is likely to become an integral part of pre-
operative assessment in the future.  
 
Further work  
Whilst the findings of this thesis are promising, further work is necessary to accurately 
determine the cut-off BNP concentration at which a particular patient’s treatment plan 
should be altered. This may vary depending on the patients’ co-morbidities but of 
particular interest would be identifying cut-off values for specific types of surgery. 
Therefore, following up from the work conducted in this thesis, a study is currently being 
conducted assessing the predictive ability of BNP (and other biochemical marker) 
concentrations specifically in patients scheduled for abdominal aortic aneurysm repair.  
 
Each biomarker (BNP, CRP, CTnI) has been assessed individually in this thesis however 
potential exists to undertake a multi-marker approach and determine whether this would 
improve the prediction of cardiac events. This could form the basis for further work in a 
larger cohort. 
 
This thesis has dealt with the predictive value of BNP and other biochemical markers in 
predicting cardiac outcome up to 6 weeks post-surgery. It would also be of benefit to 
know whether the predictive ability of BNP was maintained over a longer period. To this 
end the cohorts studied in this thesis are currently being followed up to determine the 
predictive value of BNP and other biochemical markers at 1 year. 
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Appendix 1: Information sheet/consent form 
 
THIS SHEET HAS BEEN APPROVED BY THE WEST ETHICS COMMITTEE 
 
INFORMATION SHEET FOR PATEINTS/VOLUNTEERS IN CLINICAL 
RESEARCH PROJECT 
 
Brief Title of Project 
 
Can B-type natriuretic peptide measurement aid risk assessment in general/vascular 
surgical patients? 
 
Patient’s Summary (Purpose of study, nature of procedure, discomfort and possible 
risks in terms which the patient or volunteer can understand). 
 
PARTICIPANT INFORMATION SHEET 
We invite you to take part in a research project. 
 
BACKGROUND  
Surgery is associated with a risk of problems that may arise during or after the procedure.  
Normally, a patient will be assessed for their risk of developing a problem, such as a 
heart attack or stroke.  This assessment may include clinical examination a chest x-ray, 
and sometimes, an ultrasound scan of the heart.  Despite these measures, heart attacks 
and strokes still occur. 
B-type natriuretic peptide, or BNP, is a chemical produced by the heart.  The amount of 
BNP in the blood is increased in patients with a heart problem. We are interested to know 
whether a BNP blood test could help identify patients who are at risk of having a heart 
problem around the time of vascular and general surgery. 
 
WHAT WILL HAPPEN TO YOU? 
If you decide to go ahead, your participation will involve one extra blood test at the time 
of your admission for surgery.  The blood sample will be taken from a forearm vein and 
will be 30mls in volume (i.e. three tablespoons).  This blood sample will be tested for 
BNP, and also for troponin and CRP, which are chemicals produced in the body when the 
heart is under strain.  This blood test will be repeated at 48 hours (on the ward), before 
discharge and at the outpatient clinic after your operation. 
 
CAN YOU CHANGE YOUR MIND?  WHAT WILL HAPPEN IF YOU SAY NO? 
Participation in this study may not be of direct benefit to you but information from this 
study could help in the development of treatment for patients in the future.  You should 
not take part if you are pregnant, or could become pregnant.  If you wish to take part in 
the study, your General Practitioner will be advised of your participation and the clinical 
management that you will undergo.  Participation in this study would be strictly 
confidential.  If the results show new and important findings the results may be published 
in a scientific journal in order that other doctors may learn of this new information.  The 
results would be published in a way that you cannot be identified.  No payment will be 
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made for your participation in this project.  You may not wish to participate in this study, 
or may wish to withdraw at any time after commencing the trial. In this circumstance 
your care will in no way be affected.  Should you come to any harm as a result of taking 
part in this study you may be entitled to compensation.  Taking part in this study will not 
affect your ability to drive. 
 
DO YOU HAVE TO DECIDE AT ONCE? 
Please feel free to discuss this with your relatives and then let us know your decision 
either way.  If you have any questions about the study at any time please telephone Dr SC 
Gibson at 0141 211 3000 (during or out with working hours). 
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WEST ETHICS COMMITTEE 
 
FORM OF CONSENT FOR PATIENTS/VOLUNTEERS IN CLINICAL RESEARCH PROJECT 
 
 
Title of Project 
Can B-type natriuretic peptide measurement aid risk assessment in surgical patients? 
 
By signing this form you give consent to your participation in the project whose title is at 
the top of this page. You should have been given a complete explanation of the project to 
your satisfaction and been given the opportunity to ask questions. You should have been 
given a copy of the patient information sheet approved by the West Ethics Committee to 
read and to keep. Even though you have agreed to take part in the research procedures 
you may withdraw this consent at any time without the need to explain why and without 
prejudice to your care. 
 
 
 
 
 
 
 
 
Consent: 
 
 
I,……………………………………………………………………………. (PRINT) 
 
 
of…………………………………………………………………………… 
 
give my consent to the research project above, the nature, purpose and possible consequences of 
which have been described to me  
 
 
by…………………………………………………………………………. 
 
 
Patient’s signature…………………………………………………… Date …………………………………. 
 
 
 
Doctor’s signature……………………………………………………....  
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Appendix 2: Data sheet 
 
B.N.P. Study 
 
Name 
Hospital Number 
Date of Birth 
 
Diagnosis 
Operation 
Operation date 
 
Consultant 
 
Male                            Female 
 
Smoker                       Yes         per day           No, never                 Stopped         ago 
 
Diabetic                      Yes                                No 
Previous MI                Yes                               No 
Hypertensive              Yes                                No 
 
Hyperlipidaemia         Yes                                No 
 
Angina                        Canadian classification   0           1           2        3          4  
      
Heart failure               NYHA                             0           1           2        3          4                                                                    
                                   
 LVH                           none              
                                    diuretic, digoxin, Rx for angina, hypertension 
                                    periph. Oedema, warfarin, b-line cardiomyopathy 
                                    raised JVP, cardiomegaly 
                  
COPD                         mild disease          
                                    dypsnoea on exertion 
                                    moderate, limiting dypsnoea 
                                    dypsnoea at rest, pulm. fibrosis 
                                                                                   
                                   
Renal disease             Yes                                No 
 
Cerebrovascular         CVA              TIA                    None 
disease 
 
 
 Relevant medications 
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Pulse                                         Blood pressure                                          GCS 
 
Specialised investigation                                              Result 
 
Echo 
 
Exercise testing 
 
Stress thallium 
 
Pulmonary function tests 
 
Coronary angiography 
 
 
 
Bloods                        Taken                             Result 
 
Crp 
 
 Hb 
WCC 
Platelets 
 
PT 
PTT 
pfib 
 
Na 
K 
Urea 
Creatinine 
 
Lipids -  cholesterol                                             LDL 
               Triglycerides                                         HDL 
                         
 
Magnesium 
 
Troponin 
 
 
ECG                   done                                         normal                           abnormal 
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Sats on air 
 
 
Intraoperatively 
Operation type 
CEPOD 
No. of procedures 
 
Blood loss 
Peritoneal contamination 
 
Hypothermia ( 34.5 degrees) 
 
Hypotension 
 
Beta blockers 
 
X-clamp time                                       supra-renal X-clamp 
 
Length of procedure 
 
Post operatively 
 
ITU                             days 
HDU                           days 
Ward                           days 
 
 
P-POSSUM 
 
Physiology score 
 
Operative severity score 
 
Morbidity 
 
Mortality 
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At 48 hours 
 
Bloods              Taken                          Result 
 
Urea 
Creatinine 
 
Troponin 
 
CRP 
 
 
ECG              done                                normal                       abnormal          
 
1 week 
 
Urea 
Creatinine 
 
Troponin 
ECG 
 
 
Complications 
 
 
 
 
After 6 weeks 
 
Bloods                  Taken                             Result 
 
Urea 
Creatinine 
 
Troponin 
 
CRP 
 
 
ECG             done                                 normal                        abnormal 
 
Complications in interim 
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Respiratory status                                                                       
 
 
 
New meds 
 
